Journal Article
. 2013 Oct;138(2).
doi: 10.5858/arpa.2013-0953-SA.

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update

Antonio C Wolff 1 M Elizabeth H Hammond  David G Hicks  Mitch Dowsett  Lisa M McShane  Kimberly H Allison  Donald C Allred  John M S Bartlett  Michael Bilous  Patrick Fitzgibbons  Wedad Hanna  Robert B Jenkins  Pamela B Mangu  Soonmyung Paik  Edith A Perez  Michael F Press  Patricia A Spears  Gail H Vance  Giuseppe Viale  Daniel F Hayes  American Society of Clinical Oncology  College of American Pathologists  
  • PMID: 24099077
  •     147 References
  •     304 citations


Purpose: To update the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing in breast cancer to improve the accuracy of HER2 testing and its utility as a predictive marker in invasive breast cancer.

Methods: ASCO/CAP convened an Update Committee that included coauthors of the 2007 guideline to conduct a systematic literature review and update recommendations for optimal HER2 testing.

Results: The Update Committee identified criteria and areas requiring clarification to improve the accuracy of HER2 testing by immunohistochemistry (IHC) or in situ hybridization (ISH). The guideline was reviewed and approved by both organizations.

Recommendations: The Update Committee recommends that HER2 status (HER2 negative or positive) be determined in all patients with invasive (early stage or recurrence) breast cancer on the basis of one or more HER2 test results (negative, equivocal, or positive). Testing criteria define HER2-positive status when (on observing within an area of tumor that amounts to >10% of contiguous and homogeneous tumor cells) there is evidence of protein overexpression (IHC) or gene amplification (HER2 copy number or HER2/CEP17 ratio by ISH based on counting at least 20 cells within the area). If results are equivocal (revised criteria), reflex testing should be performed using an alternative assay (IHC or ISH). Repeat testing should be considered if results seem discordant with other histopathologic findings. Laboratories should demonstrate high concordance with a validated HER2 test on a sufficiently large and representative set of specimens. Testing must be performed in a laboratory accredited by CAP or another accrediting entity. The Update Committee urges providers and health systems to cooperate to ensure the highest quality testing.

Breast core needle biopsy: issues and controversies.
Michael Bilous.
Mod Pathol, 2010 May 14; 23 Suppl 2. PMID: 20436501
A UK NEQAS ICC and ISH multicentre study using the Kreatech Poseidon HER2 FISH probe: intersite variation can be rigorously controlled using FISH.
John M S Bartlett, Fiona M Campbell, +10 authors, Keith Miller.
Histopathology, 2010 May 13; 56(3). PMID: 20459530
Determination of HER2 amplification in primary breast cancer using dual-colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: a European multicentre study involving 168 specimens.
Tomás García-Caballero, Dorthe Grabau, +6 authors, Jens Mollerup.
Histopathology, 2010 May 13; 56(4). PMID: 20459554    Free PMC article.
Age/race differences in HER2 testing and in incidence rates for breast cancer triple subtypes: a population-based study and first report.
Mary Jo Lund, Ebonee N Butler, +7 authors, J William Eley.
Cancer, 2010 Mar 26; 116(11). PMID: 20336785
Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases.
S J Aitken, J S Thomas, +2 authors, D Faratian.
Ann Oncol, 2009 Oct 28; 21(6). PMID: 19858088
American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.
M Elizabeth H Hammond, Daniel F Hayes, +29 authors, Antonio C Wolff.
J Clin Oncol, 2010 Apr 21; 28(16). PMID: 20404251    Free PMC article.
Highly Cited. Systematic Review.
Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma: comparison with FISH and assessment of interobserver reproducibility.
Bettina G Papouchado, Jonathan Myles, +22 authors, Raymond Tubbs.
Am J Surg Pathol, 2010 Apr 28; 34(6). PMID: 20421783
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.
M Elizabeth H Hammond, Daniel F Hayes, +29 authors, Antonio C Wolff.
Arch Pathol Lab Med, 2010 Jun 09; 134(6). PMID: 20524868    Free PMC article.
Highly Cited.
Study on breast carcinoma Her2/neu and hormonal receptors status assessed by automated images analysis systems: ACIS III (Dako) and ScanScope (Aperio).
Janina Słodkowska, Violetta Filas, +6 authors, Marcial Garcia Rojo.
Folia Histochem Cytobiol, 2010 Jun 10; 48(1). PMID: 20529811
Reliability of human epidermal growth factor receptor 2 immunohistochemistry in breast core needle biopsies.
Annette Lebeau, Andreas Turzynski, +10 authors, Michael Untch.
J Clin Oncol, 2010 May 26; 28(20). PMID: 20498397
Impact of clinical and non-clinical factors on the choice of HER2 test for breast cancer.
Mahima Ashok, Paul Griffin, Michael Halpern.
Cancer Invest, 2010 Jul 02; 28(7). PMID: 20590449
Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials.
Stuart D Russell, Kimberly L Blackwell, +6 authors, Kenneth W Mahaffey.
J Clin Oncol, 2010 Jun 10; 28(21). PMID: 20530275
Image analysis as an adjunct to manual HER-2 immunohistochemical review: a diagnostic tool to standardize interpretation.
Lynne Dobson, Catherine Conway, +8 authors, Elaine Kay.
Histopathology, 2010 Jun 30; 57(1). PMID: 20584089    Free PMC article.
Comparison of central HER2 testing with quantitative total HER2 expression and HER2 homodimer measurements using a novel proximity-based assay.
Weidong Huang, Monica Reinholz, +11 authors, Edith A Perez.
Am J Clin Pathol, 2010 Jul 28; 134(2). PMID: 20660336
Clinical array-based karyotyping of breast cancer with equivocal HER2 status resolves gene copy number and reveals chromosome 17 complexity.
Shelly Gunn, I-Tien Yeh, +8 authors, Mansoor Mohammed.
BMC Cancer, 2010 Jul 30; 10. PMID: 20667129    Free PMC article.
Fixation time does not affect expression of HER2/neu: a pilot study.
Julio A Ibarra, Lowell W Rogers.
Am J Clin Pathol, 2010 Sep 22; 134(4). PMID: 20855640
HER-2/neu expression in primary and metastatic breast cancer.
Elyse E Lower, Eleanor Glass, Robbin Blau, Stacy Harman.
Breast Cancer Res Treat, 2008 Feb 15; 113(2). PMID: 18273700
The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group.
Steven M Teutsch, Linda A Bradley, +7 authors, EGAPP Working Group.
Genet Med, 2008 Sep 25; 11(1). PMID: 18813139    Free PMC article.
Highly Cited.
Evaluation of automated silver-enhanced in situ hybridization (SISH) for detection of HER2 gene amplification in breast carcinoma excision and core biopsy specimens.
S Shousha, D Peston, +2 authors, B Jasani.
Histopathology, 2009 Feb 12; 54(2). PMID: 19207950
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.
Luca Gianni, Urania Dafni, +23 authors, Herceptin Adjuvant (HERA) Trial Study Team.
Lancet Oncol, 2011 Mar 01; 12(3). PMID: 21354370
Highly Cited.
The effect of prolonged fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast cancer: a prospective study.
Leung Chu Tong, Nahid Nelson, Jim Tsourigiannis, Anna Marie Mulligan.
Am J Surg Pathol, 2011 Mar 02; 35(4). PMID: 21358301
Clinical Notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer.
M Elizabeth Hammond, Daniel F Hayes, Antonio C Wolff.
J Clin Oncol, 2011 Apr 20; 29(15). PMID: 21502545
Heterogeneous HER2 gene amplification: impact on patient outcome and a clinically relevant definition.
Alastair I Bartlett, Jane Starcyznski, +8 authors, John M S Bartlett.
Am J Clin Pathol, 2011 Jul 16; 136(2). PMID: 21757600
Effects of the change in cutoff values for human epidermal growth factor receptor 2 status by immunohistochemistry and fluorescence in situ hybridization: a study comparing conventional brightfield microscopy, image analysis-assisted microscopy, and interobserver variation.
Roscoe Atkinson, Jens Mollerup, +7 authors, Kirsten Vang Nielsen.
Arch Pathol Lab Med, 2011 Aug 04; 135(8). PMID: 21809992
Very high quantitative tumor HER2 content and outcome in early breast cancer.
H Joensuu, J Sperinde, +12 authors, M Bates.
Ann Oncol, 2011 Feb 03; 22(9). PMID: 21285132
Identification of a subpopulation of metastatic breast cancer patients with very high HER2 expression levels and possible resistance to trastuzumab.
M Bates, J Sperinde, +12 authors, A Lipton.
Ann Oncol, 2011 Feb 04; 22(9). PMID: 21289364
Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.
Edith A Perez, Edward H Romond, +7 authors, Norman Wolmark.
J Clin Oncol, 2011 Jul 20; 29(25). PMID: 21768458    Free PMC article.
Highly Cited.
Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy.
Chun Hing Tse, Harry C Hwang, +4 authors, Allen M Gown.
J Clin Oncol, 2011 Sep 29; 29(31). PMID: 21947821
High false-negative rate of HER2 quantitative reverse transcription polymerase chain reaction of the Oncotype DX test: an independent quality assurance study.
David J Dabbs, Molly E Klein, +3 authors, Rohit Bhargava.
J Clin Oncol, 2011 Oct 13; 29(32). PMID: 21990395
Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer.
Jack Cuzick, Mitch Dowsett, +10 authors, John F Forbes.
J Clin Oncol, 2011 Oct 13; 29(32). PMID: 21990413
Highly Cited.
HER2 evaluation and its impact on breast cancer treatment decisions.
K A B Goddard, S Weinmann, +3 authors, C Wax.
Public Health Genomics, 2011 May 05; 15(1). PMID: 21540562    Free PMC article.
HER2 genetic heterogeneity in breast carcinoma.
Christian Ohlschlegel, Katharina Zahel, +2 authors, Wolfram Jochum.
J Clin Pathol, 2011 Oct 21; 64(12). PMID: 22011446
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.
José Baselga, Javier Cortés, +12 authors, CLEOPATRA Study Group.
N Engl J Med, 2011 Dec 14; 366(2). PMID: 22149875    Free PMC article.
Highly Cited.
Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria.
Edith A Perez, Amylou C Dueck, +9 authors, Beiyun Chen.
J Natl Cancer Inst, 2011 Dec 06; 104(2). PMID: 22138096    Free PMC article.
Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors.
Naoki Niikura, Jun Liu, +7 authors, Naoto T Ueno.
J Clin Oncol, 2011 Nov 30; 30(6). PMID: 22124109    Free PMC article.
Highly Cited.
Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial.
Joseph A Sparano, Molin Wang, +9 authors, Nancy E Davidson.
J Natl Cancer Inst, 2012 Jan 18; 104(5). PMID: 22250182    Free PMC article.
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.
Marco Gerlinger, Andrew J Rowan, +28 authors, Charles Swanton.
N Engl J Med, 2012 Mar 09; 366(10). PMID: 22397650    Free PMC article.
Highly Cited.
HER2 gene amplification in breast cancer: a rogues' gallery of challenging diagnostic cases: UKNEQAS interpretation guidelines and research recommendations.
Jane Starczynski, Neil Atkey, +8 authors, UKNEQAS.
Am J Clin Pathol, 2012 Mar 21; 137(4). PMID: 22431536
HER2-negative (1+) breast cancer with unfavorable prognostic features: to FISH or not to FISH?
M Iorfida, S Dellapasqua, +7 authors, M Colleoni.
Ann Oncol, 2012 Mar 14; 23(5). PMID: 22412042
'Genetic heterogeneity' in HER2/neu testing by fluorescence in situ hybridization: a study of 2,522 cases.
Martin C Chang, Janet I Malowany, Julita Mazurkiewicz, Martha Wood.
Mod Pathol, 2012 Jan 28; 25(5). PMID: 22282306
Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies.
Eitan Amir, Mark Clemons, +7 authors, Alastair M Thompson.
Cancer Treat Rev, 2011 Dec 20; 38(6). PMID: 22178456
Re: predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria.
Antonio C Wolff, M Elizabeth Hammond, Daniel F Hayes.
J Natl Cancer Inst, 2012 May 15; 104(12). PMID: 22581974
Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study.
Erin J Aiello Bowles, Robert Wellman, +13 authors, Pharmacovigilance Study Team.
J Natl Cancer Inst, 2012 Sep 06; 104(17). PMID: 22949432    Free PMC article.
Highly Cited.
Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer.
Edward H Romond, Jong-Hyeon Jeong, +18 authors, Norman Wolmark.
J Clin Oncol, 2012 Sep 19; 30(31). PMID: 22987084    Free PMC article.
Highly Cited.
Trastuzumab emtansine for HER2-positive advanced breast cancer.
Sunil Verma, David Miles, +12 authors, EMILIA Study Group.
N Engl J Med, 2012 Oct 02; 367(19). PMID: 23020162    Free PMC article.
Highly Cited.
Closing the personalized medicine information gap: HER2 test documentation practice.
Ilia L Ferrusi, Craig C Earle, +5 authors, Deborah A Marshall.
Am J Manag Care, 2013 Feb 06; 19(1). PMID: 23379747    Free PMC article.
Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005).
Edith A Perez, Michael F Press, +15 authors, Dennis J Slamon.
Breast Cancer Res Treat, 2013 Feb 20; 138(1). PMID: 23420271    Free PMC article.
Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
Sara A Hurvitz, Luc Dirix, +9 authors, Edith A Perez.
J Clin Oncol, 2013 Feb 06; 31(9). PMID: 23382472
Highly Cited.
HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity.
Wedad M Hanna, Josef Rüschoff, +6 authors, Giuseppe Viale.
Mod Pathol, 2013 Jun 29; 27(1). PMID: 23807776
Highly Cited. Review.
Preoperative assessment of HER-2/neu status in breast carcinoma: the role of quantitative real-time PCR on core-biopsy specimens.
Tommaso Susini, Cecilia Bussani, +9 authors, Gianfranco Scarselli.
Gynecol Oncol, 2009 Nov 19; 116(2). PMID: 19919879
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
D J Slamon, B Leyland-Jones, +9 authors, L Norton.
N Engl J Med, 2001 Mar 15; 344(11). PMID: 11248153
Highly Cited.
Effect of prolonged formalin fixation on the immunohistochemical reactivity of breast markers.
Daniel A Arber.
Appl Immunohistochem Mol Morphol, 2002 Jun 08; 10(2). PMID: 12051639
Influence of health insurance status on inclusion of HER-2/neu testing in the diagnostic workup of breast cancer patients.
Azadeh Stark, Gena Kucera, +2 authors, Jennifer Griggs.
Int J Qual Health Care, 2004 Nov 24; 16(6). PMID: 15557362
Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm.
Wedad M Hanna, Kevin Kwok.
Mod Pathol, 2006 Jan 31; 19(4). PMID: 16444193
Concordance between central and local laboratory HER2 testing from a community-based clinical study.
Josina C Reddy, James D Reimann, Steven M Anderson, Pamela M Klein.
Clin Breast Cancer, 2006 Jun 28; 7(2). PMID: 16800975
HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial.
Edith A Perez, Vera J Suman, +7 authors, Robert B Jenkins.
J Clin Oncol, 2006 Jul 01; 24(19). PMID: 16809727
Highly Cited.
HER-2 gene amplification by chromogenic in situ hybridisation (CISH) compared with fluorescence in situ hybridisation (FISH) in breast cancer-A study of two hundred cases.
A Sáez, F J Andreu, +4 authors, M Rey.
Breast, 2005 Nov 18; 15(4). PMID: 16290155
Chromogenic in situ hybridization to detect HER-2/neu gene amplification in histological and ThinPrep-processed breast cancer fine-needle aspirates: a sensitive and practical method in the trastuzumab era.
Amina Vocaturo, Flavia Novelli, +8 authors, Marcella Mottolese.
Oncologist, 2006 Sep 05; 11(8). PMID: 16951391
Evaluation of Her-2/neu status in carcinomas with amplified chromosome 17 centromere locus.
Megan L Troxell, Charles D Bangs, +5 authors, Athena M Cherry.
Am J Clin Pathol, 2006 Oct 20; 126(5). PMID: 17050068
Automation of manual components and image quantification of direct dual label fluorescence in situ hybridization (FISH) for HER2 gene amplification: A feasibility study.
Raymond R Tubbs, James D Pettay, +4 authors, Thomas Grogan.
Appl Immunohistochem Mol Morphol, 2006 Nov 24; 14(4). PMID: 17122642
A comparative assessment of HER2 status in operable breast cancer by real-time RT-PCR and by immunohistochemistry.
Piotr Potemski, Elzbieta Płuciennik, +5 authors, Radzisław Kordek.
Med Sci Monit, 2006 Dec 01; 12(12). PMID: 17136015
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Charles E Geyer, John Forster, +15 authors, David Cameron.
N Engl J Med, 2006 Dec 29; 355(26). PMID: 17192538
Highly Cited.
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
Antonio C Wolff, M Elizabeth H Hammond, +22 authors, College of American Pathologists.
J Clin Oncol, 2006 Dec 13; 25(1). PMID: 17159189
Highly Cited.
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.
Ian Smith, Marion Procter, +22 authors, HERA study team.
Lancet, 2007 Jan 09; 369(9555). PMID: 17208639
Highly Cited.
HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management?
A Vincent-Salomon, J-Y Pierga, +8 authors, X Sastre-Garau.
Br J Cancer, 2007 Jan 31; 96(4). PMID: 17262082    Free PMC article.
Tissue microarray technology in breast cancer HER2 diagnostics.
Kristof Egervari, Zoltan Szollosi, Zoltan Nemes.
Pathol Res Pract, 2007 Feb 13; 203(3). PMID: 17292562
A modified approach for I-FISH evaluation of ERBB2 (HER-2) gene copy numbers in breast carcinomas: comparison with HER-2/CEP17 ratio system.
Marcela Mrhalova, Roman Kodet.
J Cancer Res Clin Oncol, 2006 Dec 14; 133(5). PMID: 17165026
Standardization of HER2 testing: results of an international proficiency-testing ring study.
Mitch Dowsett, Wedad M Hanna, +5 authors, Marc J van de Vijver.
Mod Pathol, 2007 Mar 31; 20(5). PMID: 17396141
Quantitative real-time PCR analysis and microarray-based RNA expression of HER2 in relation to outcome.
J Bergqvist, J F Ohd, +9 authors, J Bergh.
Ann Oncol, 2007 Mar 14; 18(5). PMID: 17351254
Borderline HER-2 breast cancer cases: histochemical versus real-time PCR analysis and impact of different cut-off values.
G Monego, V Arena, +6 authors, A Carbone.
Scand J Clin Lab Invest, 2007 Jun 15; 67(4). PMID: 17558895
Evaluation of HER2/neu gene amplification in patients with invasive breast carcinoma. Comparison of in situ hybridization methods.
Anna Sińczak-Kuta, Romana Tomaszewska, +2 authors, Jerzy Stachura.
Pol J Pathol, 2007 Jun 26; 58(1). PMID: 17585541
HER2 gene status in primary breast cancers and matched distant metastases.
Coya Tapia, Spasenija Savic, +10 authors, Lukas Bubendorf.
Breast Cancer Res, 2007 May 22; 9(3). PMID: 17511881    Free PMC article.
A comparison of immunohistochemical staining for oestrogen receptor, progesterone receptor and HER-2 in breast core biopsies and subsequent excisions.
Benjamin Wood, Reimar Junckerstorff, +3 authors, Peter Robbins.
Pathology, 2007 Aug 07; 39(4). PMID: 17676479
PGDS, a novel technique combining chromogenic in situ hybridization and immunohistochemistry for the assessment of ErbB2 (HER2/neu) status in breast cancer.
Ruoyu Ni, Anna Marie Mulligan, Cherry Have, Frances P O'Malley.
Appl Immunohistochem Mol Morphol, 2007 Aug 28; 15(3). PMID: 17721278
HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas.
Sara Alexandra Vinhas Ricardo, Fernanda Milanezi, +2 authors, Fernando Carlos Lander Schmitt.
J Clin Pathol, 2006 Dec 13; 60(9). PMID: 17158643    Free PMC article.
Chromogenic in situ hybridisation (CISH) should be an accepted method in the routine diagnostic evaluation of HER2 status in breast cancer.
S Di Palma, N Collins, +6 authors, M G Cook.
J Clin Pathol, 2007 Feb 13; 60(9). PMID: 17293390    Free PMC article.
Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy.
John M S Bartlett, Ian O Ellis, +10 authors, Paul Ellis.
J Clin Oncol, 2007 Oct 02; 25(28). PMID: 17906205
Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.
Michail Ignatiadis, Nikos Xenidis, +10 authors, Dimitris Mavroudis.
J Clin Oncol, 2007 Oct 24; 25(33). PMID: 17954712
Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcome.
Christopher B Moeder, Jennifer M Giltnane, +8 authors, College of American Pathologists.
J Clin Oncol, 2007 Dec 01; 25(34). PMID: 18048824
Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer.
Luca Gianni, Anna Lladó, +9 authors, José Baselga.
J Clin Oncol, 2010 Feb 04; 28(7). PMID: 20124183    Free PMC article.
Real-time RT-PCR analysis for evaluating the Her2/neu status in breast cancer.
M Cuadros, P Talavera, +3 authors, A Concha.
Pathobiology, 2010 Feb 27; 77(1). PMID: 20185966
Accurately assessing her-2/neu status in needle core biopsies of breast cancer patients in the era of neoadjuvant therapy: emerging questions and considerations addressed.
Timothy D'Alfonso, Yi-Fang Liu, +2 authors, Sandra J Shin.
Am J Surg Pathol, 2010 Mar 11; 34(4). PMID: 20216378
Comparison of Pathvysion and Poseidon HER2 FISH assays in measuring HER2 amplification in breast cancer: a validation study.
Monika Francz, Kristof Egervari, +4 authors, Zoltan Szollosi.
J Clin Pathol, 2009 Dec 08; 63(4). PMID: 19965795
Comparing subjective and digital image analysis HER2/neu expression scores with conventional and modified FISH scores in breast cancer.
I Skaland, I Øvestad, +4 authors, J P A Baak.
J Clin Pathol, 2007 Apr 07; 61(1). PMID: 17412872
Comparison of different commercial kits for HER2 testing in breast cancer: looking for the accurate cutoff for amplification.
Anne Cayre, Florence Mishellany, Nicole Lagarde, Frédérique Penault-Llorca.
Breast Cancer Res, 2007 Oct 03; 9(5). PMID: 17908324    Free PMC article.
Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study.
Marc van de Vijver, Michael Bilous, +4 authors, Josef Rüschoff.
Breast Cancer Res, 2007 Oct 10; 9(5). PMID: 17922920    Free PMC article.
National HER2 proficiency test results using standardized quantitative controls: characterization of laboratory failures.
Kodela Vani, Seshi R Sompuram, Patrick Fitzgibbons, Steven A Bogen.
Arch Pathol Lab Med, 2008 Feb 07; 132(2). PMID: 18251579
Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial.
Edith A Perez, Vera J Suman, +12 authors, Richard J Rodeheffer.
J Clin Oncol, 2008 Feb 06; 26(8). PMID: 18250349    Free PMC article.
Highly Cited.
Quantitative PCR and HER2 testing in breast cancer: a technical and cost-effectiveness analysis.
Massimo Barberis, Caterina Pellegrini, +3 authors, Silvano Bosari.
Am J Clin Pathol, 2008 Mar 18; 129(4). PMID: 18343783
Clinical importance of HER2 immunohistologic heterogeneous expression in core-needle biopsies vs resection specimens for equivocal (immunohistochemical score 2+) cases.
Mamatha Chivukula, Rohit Bhargava, +2 authors, David J Dabbs.
Mod Pathol, 2008 Feb 05; 21(4). PMID: 18246053
HER2 status and benefit from adjuvant trastuzumab in breast cancer.
Soonmyung Paik, Chungyeul Kim, Norman Wolmark.
N Engl J Med, 2008 Mar 28; 358(13). PMID: 18367751
Highly Cited.
Digital image analysis improves the quality of subjective HER-2 expression scoring in breast cancer.
Ivar Skaland, Irene Ovestad, +4 authors, Jan P A Baak.
Appl Immunohistochem Mol Morphol, 2008 Jan 30; 16(2). PMID: 18227722
Lower HER-2/chromosome enumeration probe 17 ratio in cytologic HER-2 fluorescence in situ hybridization for breast cancers: three-dimensional analysis of intranuclear localization of centromere 17 and HER-2 signals.
Hitoshi Itoh, Yoko Miyajima, Shinobu Umemura, Robert Y Osamura.
Cancer, 2008 Feb 29; 114(2). PMID: 18306351
HER-2/neu assessment in breast cancer using the original FDA and new ASCO/CAP guideline recommendations: impact on selecting patients for herceptin therapy.
Matteo Brunelli, Erminia Manfrin, +5 authors, Franco Bonetti.
Am J Clin Pathol, 2008 May 16; 129(6). PMID: 18480007
Tissue microarray technology in the routine assessment of HER-2 status in invasive breast cancer: a prospective study of the use of immunohistochemistry and fluorescence in situ hybridization.
A D Graham, D Faratian, F Rae, J St J Thomas.
Histopathology, 2008 May 23; 52(7). PMID: 18494613
Computer-assisted assessment of the human epidermal growth factor receptor 2 immunohistochemical assay in imaged histologic sections using a membrane isolation algorithm and quantitative analysis of positive controls.
Bonnie H Hall, Monica Ianosi-Irimie, +3 authors, David J Foran.
BMC Med Imaging, 2008 Jun 07; 8. PMID: 18534031    Free PMC article.
Comparative analysis of six different antibodies against Her2 including the novel rabbit monoclonal antibody (SP3) and chromogenic in situ hybridisation in breast carcinomas.
C B Nunes, R M Rocha, +5 authors, H Gobbi.
J Clin Pathol, 2008 May 14; 61(8). PMID: 18474540
Using a higher cutoff for the percentage of HER2+ cells decreases interobserver variability in the interpretation of HER2 immunohistochemical analysis.
Omar Hameed, Amy L Adams, +7 authors, Thomas Winokur.
Am J Clin Pathol, 2008 Aug 15; 130(3). PMID: 18701416
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management.
Valentina Guarneri, Simona Giovannelli, +8 authors, PierFranco Conte.
Oncologist, 2008 Jul 25; 13(8). PMID: 18650259
High concordance of SP3 rabbit monoclonal antibody with FISH to evaluate HER2 in breast carcinoma.
Sheila C L Wludarski, Carlos E Bacchi.
Appl Immunohistochem Mol Morphol, 2008 Jul 18; 16(5). PMID: 18633320
Histopathologic variables predict Oncotype DX recurrence score.
Melina B Flanagan, David J Dabbs, +2 authors, Rohit Bhargava.
Mod Pathol, 2008 Mar 25; 21(10). PMID: 18360352
Practice of HER-2 immunohistochemistry in breast carcinoma in Austria.
A Reiner-Concin, P Regitnig, +5 authors, M Rudas.
Pathol Oncol Res, 2008 Aug 30; 14(3). PMID: 18752057
Application of liquid-based preparation to fine needle aspiration cytology in breast cancer.
Kyoko Komatsu, Yoko Nakanishi, +6 authors, Norimichi Nemoto.
Acta Cytol, 2008 Oct 07; 52(5). PMID: 18833823
Comparison of quantitative immunofluorescence with conventional methods for HER2/neu testing with respect to response to trastuzumab therapy in metastatic breast cancer.
Jennifer M Giltnane, Annette Molinaro, +5 authors, David L Rimm.
Arch Pathol Lab Med, 2008 Oct 07; 132(10). PMID: 18834223
Delineation of HER2 gene status in breast carcinoma by silver in situ hybridization is reproducible among laboratories and pathologists.
Antonino Carbone, Gerardo Botti, +9 authors, Paolo Verderio.
J Mol Diagn, 2008 Oct 04; 10(6). PMID: 18832456    Free PMC article.
Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing.
Isabelle Vanden Bempt, Peter Van Loo, +5 authors, Christiane De Wolf-Peeters.
J Clin Oncol, 2008 Sep 17; 26(30). PMID: 18794552
Determination of HER2 amplification by in situ hybridization: when should chromosome 17 also be determined?
John M S Bartlett, Fiona M Campbell, Elizabeth A Mallon.
Am J Clin Pathol, 2008 Nov 21; 130(6). PMID: 19019769
A new rabbit monoclonal antibody (4B5) for the immuno-histochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibility.
William C Powell, Patrick C Roche, Raymond R Tubbs.
Appl Immunohistochem Mol Morphol, 2008 Oct 22; 16(6). PMID: 18931613
Real time RT-PCR approach for the evaluation of ERBB2 overexpression in breast cancer archival samples: a comparative study with FISH, SISH, and immunohistochemistry.
Elisa Capizzi, Elisa Gruppioni, +4 authors, Michelangelo Fiorentino.
Diagn Mol Pathol, 2008 Apr 03; 17(4). PMID: 18382352
HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
Michael F Press, Richard S Finn, +15 authors, Maria T Koehler.
Clin Cancer Res, 2008 Dec 03; 14(23). PMID: 19047115
External quality assurance of HER2 FISH and ISH testing: three years of the UK national external quality assurance scheme.
John M S Bartlett, Merdol Ibrahim, +8 authors, Keith Miller.
Am J Clin Pathol, 2008 Dec 20; 131(1). PMID: 19095573
Comprehensive immunohistochemical analysis of Her-2/neu oncoprotein overexpression in breast cancer: HercepTest (Dako) for manual testing and Her-2/neuTest 4B5 (Ventana) for Ventana BenchMark automatic staining system with correlation to results of fluorescence in situ hybridization (FISH).
Doris Mayr, Sibylle Heim, +2 authors, Thomas Kirchner.
Virchows Arch, 2009 Jan 27; 454(3). PMID: 19169706
Effect of high copy number of HER2 associated with polysomy 17 on HER2 protein expression in invasive breast carcinoma.
Sejal S Shah, Yan Wang, Jamie Tull, Shengle Zhang.
Diagn Mol Pathol, 2009 Feb 14; 18(1). PMID: 19214111
Prediction of HER2 gene status in Her2 2+ invasive breast cancer: a study of 108 cases comparing ASCO/CAP and FDA recommendations.
Frédéric Chibon, Isabelle de Mascarel, +5 authors, Gaëtan MacGrogan.
Mod Pathol, 2008 Dec 09; 22(3). PMID: 19060846
Rapid screening of tissue microarrays for Her-2 fluorescence in situ hybridization testing is an accurate, efficient and economic method of providing an entirely in situ hybridization-based Her-2 testing service.
Dana Faratian, Ashley Graham, Frances Rae, Jeremy Thomas.
Histopathology, 2009 Mar 25; 54(4). PMID: 19309394
Whether to determine HER2 status for breast cancer in the primary tumour or in the metastasis.
M P Santiago, A Vázquez-Boquete, +5 authors, T García-Caballero.
Histol Histopathol, 2009 Apr 02; 24(6). PMID: 19337966
Fine-needle aspiration for nucleic acid-ased molecular analyses in breast cancer.
Catherine Uzan, Fabrice Andre, +7 authors, Philippe Vielh.
Cancer, 2009 Apr 07; 117(1). PMID: 19347827
Even low-level HER2 expression may be associated with worse outcome in node-positive breast cancer.
Michael Z Gilcrease, Wendy A Woodward, +5 authors, Thomas A Buchholz.
Am J Surg Pathol, 2009 Mar 03; 33(5). PMID: 19252432    Free PMC article.
Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines.
Gail H Vance, Todd S Barry, +7 authors, College of American Pathologists.
Arch Pathol Lab Med, 2009 Apr 28; 133(4). PMID: 19391661
Implementation of American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Recommendations in a tertiary care facility increases HER2 immunohistochemistry and fluorescence in situ hybridization concordance and decreases the number of inconclusive cases.
Lavinia P Middleton, Kathy M Price, +5 authors, Michael T Deavers.
Arch Pathol Lab Med, 2009 May 07; 133(5). PMID: 19415952
The correlation between dual-color chromogenic in situ hybridization and fluorescence in situ hybridization in assessing HER2 gene amplification in breast cancer.
Marianne Pedersen, Birgitte Bruun Rasmussen.
Diagn Mol Pathol, 2009 May 12; 18(2). PMID: 19430295
Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome.
Glenn D Francis, Mark A Jones, Geoffrey F Beadle, Sandra R Stein.
Diagn Mol Pathol, 2009 May 12; 18(2). PMID: 19430296
HER-2/neu analysis in breast cancer bone metastases.
J Zustin, K Boddin, +9 authors, G Sauter.
J Clin Pathol, 2009 May 29; 62(6). PMID: 19474354
Automated quantitative assessment of HER-2/neu immunohistochemical expression in breast cancer.
Hela Masmoudi, Stephen M Hewitt, +2 authors, Marios A Gavrielides.
IEEE Trans Med Imaging, 2009 Jan 24; 28(6). PMID: 19164073    Free PMC article.
Rabbit antibodies for hormone receptors and HER2 evaluation in breast cancer.
Rafael Malagoli Rocha, Cristiana Buzelin Nunes, +5 authors, Helenice Gobbi.
Rev Assoc Med Bras (1992), 2009 Jun 03; 55(2). PMID: 19488652
Development of an unsupervised pixel-based clustering algorithm for compartmentalization of immunohistochemical expression using Automated QUantitative Analysis.
Mark D Gustavson, Brian Bourke-Martin, +5 authors, Jason Christiansen.
Appl Immunohistochem Mol Morphol, 2009 Mar 26; 17(4). PMID: 19318915
Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial.
Mitch Dowsett, Marion Procter, +11 authors, Brian Leyland-Jones.
J Clin Oncol, 2009 Apr 15; 27(18). PMID: 19364966    Free PMC article.
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
Antonio C Wolff, M Elizabeth H Hammond, +21 authors, American Society of Clinical Oncology/College of American Pathologists.
Arch Pathol Lab Med, 2007 Jan 01; 131(1). PMID: 19548375
Highly Cited.
Performance of chromogenic in situ hybridization on testing HER2 Status in breast carcinomas with chromosome 17 polysomy and equivocal (2+) herceptest results: a study of two institutions using the conventional and new ASCO/CAP scoring criteria.
Yun Gong, William Sweet, +6 authors, Nour Sneige.
Am J Clin Pathol, 2009 Jul 17; 132(2). PMID: 19605817
Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis.
Caterina Marchiò, Maryou B Lambros, +11 authors, Anna Sapino.
J Pathol, 2009 Aug 12; 219(1). PMID: 19670217
Immunohistochemical detection of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast carcinomas: comparison on cell block, needle-core, and tissue block preparations.
Krisztina Z Hanley, George G Birdsong, Cynthia Cohen, Momin T Siddiqui.
Cancer, 2009 Jun 25; 117(4). PMID: 19551847
Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event.
I-Tien Yeh, Mathew A Martin, +6 authors, Shelly R Gunn.
Mod Pathol, 2009 May 19; 22(9). PMID: 19448591
Comparison of fluorescent in situ hybridization HER-2/neu results on core needle biopsy and excisional biopsy in primary breast cancer.
Sophia K Apple, Alarice C Lowe, +2 authors, Neda A Moatamed.
Mod Pathol, 2009 Jun 02; 22(9). PMID: 19483670
Reply to G. Sauter et al.
Elizabeth H Hammond, Antonio C Wolff, Daniel F Hayes, Jared N Schwartz.
J Clin Oncol, 2009 Sep 10; 27(30). PMID: 19738107
Automated cellular imaging system III for assessing HER2 status in breast cancer specimens: development of a standardized scoring method that correlates with FISH.
Douglas M Minot, Benjamin R Kipp, +5 authors, Amy C Clayton.
Am J Clin Pathol, 2009 Oct 30; 132(1). PMID: 19864244
Delay to formalin fixation effect on breast biomarkers.
Thaer Khoury, Sheila Sait, +4 authors, Swati Kulkarni.
Mod Pathol, 2009 Sep 08; 22(11). PMID: 19734848
Use of archived specimens in evaluation of prognostic and predictive biomarkers.
Richard M Simon, Soonmyung Paik, Daniel F Hayes.
J Natl Cancer Inst, 2009 Oct 10; 101(21). PMID: 19815849    Free PMC article.
Highly Cited.
Estimation of hormone receptor status and HER2 in cytologic cell blocks from breast cancer using the novel rabbit monoclonal antibodies (SP1, SP2, and SP3).
Aziza Nassar, Cynthia Cohen, Momin Siddiqui.
Diagn Cytopathol, 2009 Jun 17; 37(12). PMID: 19530101
Microarray-based determination of estrogen receptor, progesterone receptor, and HER2 receptor status in breast cancer.
Paul Roepman, Hugo M Horlings, +6 authors, Marc J van de Vijver.
Clin Cancer Res, 2009 Nov 06; 15(22). PMID: 19887485
Comparison of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) assessment for Her-2 status in breast cancer.
Weiguo Sui, Minglin Ou, +5 authors, Yong Dai.
World J Surg Oncol, 2009 Nov 10; 7. PMID: 19895711    Free PMC article.
Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC).
M Arnedos, A Nerurkar, +3 authors, M Dowsett.
Ann Oncol, 2009 Jul 03; 20(12). PMID: 19570962
Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes.
Elizabeth A Mittendorf, Yun Wu, +10 authors, Ana M Gonzalez-Angulo.
Clin Cancer Res, 2009 Nov 19; 15(23). PMID: 19920100    Free PMC article.
Chromogenic in situ hybridization for Her-2/neu-oncogene in breast cancer: comparison of a new dual-colour chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization.
Doris Mayr, Sibylle Heim, +4 authors, Thomas Kirchner.
Histopathology, 2009 Nov 20; 55(6). PMID: 19922593
HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial.
Edith A Perez, Monica M Reinholz, +14 authors, Robert B Jenkins.
J Clin Oncol, 2010 Aug 11; 28(28). PMID: 20697084    Free PMC article.
Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories.
Frederick L Baehner, Ninah Achacoso, +5 authors, Laurel A Habel.
J Clin Oncol, 2010 Aug 11; 28(28). PMID: 20697093
HER2 status in a population-derived breast cancer cohort: discordances during tumor progression.
Ulla Wilking, Eva Karlsson, +6 authors, Jonas Bergh.
Breast Cancer Res Treat, 2010 Jul 16; 125(2). PMID: 20628810
A UK NEQAS ISH multicenter ring study using the Ventana HER2 dual-color ISH assay.
J M S Bartlett, Fiona M Campbell, +8 authors, Keith Miller.
Am J Clin Pathol, 2010 Dec 22; 135(1). PMID: 21173138
Androgen receptor status is a prognostic marker in non-basal triple negative breast cancers and determines novel therapeutic options.
Pierluigi Gasparini, Matteo Fassan, +11 authors, Kay Huebner.
PLoS One, 2014 Feb 08; 9(2). PMID: 24505496    Free PMC article.
Metaplastic carcinoma of the breast: an immunohistochemical study.
Fadwa J Altaf, Ghadeer A Mokhtar, +4 authors, Zuhoor K Al-Gaithy.
Diagn Pathol, 2014 Jul 18; 9. PMID: 25030022    Free PMC article.
Androgen receptor (AR) expression in 400 breast carcinomas: is routine AR assessment justified?
Damoun Safarpour, Shabnam Pakneshan, Fattaneh A Tavassoli.
Am J Cancer Res, 2014 Jul 25; 4(4). PMID: 25057438    Free PMC article.
Adjusting breast cancer patient prognosis with non-HER2-gene patterns on chromosome 17.
Vassiliki Kotoula, Mattheos Bobos, +12 authors, George Fountzilas.
PLoS One, 2014 Aug 08; 9(8). PMID: 25098819    Free PMC article.
Assessment of HER2 testing patterns, HER2+ disease, and the utilization of HER2-directed therapy in early breast cancer.
David D Stenehjem, Minkyoung Yoo, +6 authors, Diana I Brixner.
Breast Cancer (Dove Med Press), 2014 Nov 08; 6. PMID: 25378949    Free PMC article.
Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer.
Costanza Paoletti, Maria C Muñiz, +13 authors, Daniel F Hayes.
Clin Cancer Res, 2014 Nov 09; 21(11). PMID: 25381338    Free PMC article.
Prognostic role of HER2 expression in bladder cancer: a systematic review and meta-analysis.
Junjie Zhao, Weidong Xu, +4 authors, Chuanliang Xu.
Int Urol Nephrol, 2014 Nov 12; 47(1). PMID: 25384433
Systematic Review.
Transfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technology.
Debora Fumagalli, Alexis Blanchet-Cohen, +13 authors, Benjamin Haibe-Kains.
BMC Genomics, 2014 Nov 22; 15. PMID: 25412710    Free PMC article.
FISH molecular testing in cytological preparations from solid tumors.
Paola Caria, Roberta Vanni.
Mol Cytogenet, 2014 Dec 06; 7. PMID: 25478010    Free PMC article.
An international study to increase concordance in Ki67 scoring.
Mei-Yin C Polley, Samuel C Y Leung, +28 authors, Torsten O Nielsen.
Mod Pathol, 2015 Feb 24; 28(6). PMID: 25698062
Highly Cited.
Mutant allele tumor heterogeneity (MATH) and head and neck squamous cell carcinoma.
James W Rocco.
Head Neck Pathol, 2015 Mar 26; 9(1). PMID: 25804377    Free PMC article.
Optimal systemic therapy for early breast cancer in women: a clinical practice guideline.
A Eisen, G G Fletcher, +5 authors, members of the Early Breast Cancer Systemic Therapy Consensus Panel.
Curr Oncol, 2015 Apr 08; 22(Suppl 1). PMID: 25848340    Free PMC article.
Copy number gain of granulin-epithelin precursor (GEP) at chromosome 17q21 associates with overexpression in human liver cancer.
Man Kuen Yung, Kwok Wai Lo, +8 authors, Siu Tim Cheung.
BMC Cancer, 2015 Apr 18; 15. PMID: 25885205    Free PMC article.
Quantification of HER family receptors in breast cancer.
Paolo Nuciforo, Nina Radosevic-Robin, Tony Ng, Maurizio Scaltriti.
Breast Cancer Res, 2015 Apr 19; 17. PMID: 25887735    Free PMC article.
Cytogenomic profiling of breast cancer brain metastases reveals potential for repurposing targeted therapeutics.
Aliccia Bollig-Fischer, Sharon K Michelhaugh, +7 authors, Sandeep Mittal.
Oncotarget, 2015 May 15; 6(16). PMID: 25970776    Free PMC article.
Differential CARM1 Isoform Expression in Subcellular Compartments and among Malignant and Benign Breast Tumors.
David Shlensky, Jennifer A Mirrielees, +6 authors, Wei Xu.
PLoS One, 2015 Jun 02; 10(6). PMID: 26030442    Free PMC article.
Prognostic Value of Beta-Tubulin-3 and c-Myc in Muscle Invasive Urothelial Carcinoma of the Bladder.
Francesco Massari, Emilio Bria, +9 authors, Matteo Brunelli.
PLoS One, 2015 Jun 06; 10(6). PMID: 26046361    Free PMC article.
The Therapeutic Challenge of Targeting HER2 in Endometrial Cancer.
Elisabeth J Diver, Rosemary Foster, Bo R Rueda, Whitfield B Growdon.
Oncologist, 2015 Jun 24; 20(9). PMID: 26099744    Free PMC article.
Breast Cancer Outcomes as Defined by the Estrogen Receptor, Progesterone Receptor, and Human Growth Factor Receptor-2 in a Multi-ethnic Asian Country.
S Subramaniam, N Bhoo-Pathy, +6 authors, C H Yip.
World J Surg, 2015 Jul 04; 39(10). PMID: 26138872
Specific upregulation of RHOA and RAC1 in cancer-associated fibroblasts found at primary tumor and lymph node metastatic sites in breast cancer.
Patricia Bortman Rozenchan, Fatima Solange Pasini, +5 authors, Maria Mitzi Brentani.
Tumour Biol, 2015 Jul 06; 36(12). PMID: 26142737
Modeling Canadian Quality Control Test Program for Steroid Hormone Receptors in Breast Cancer: Diagnostic Accuracy Study.
Teresa Pérez, Nikita Makrestsov, +3 authors, Susan Mallett.
Appl Immunohistochem Mol Morphol, 2015 Jul 23; 24(10). PMID: 26200834    Free PMC article.
Clinical Significance of Substaging and HER2 Expression in Papillary Nonmuscle Invasive Urothelial Cancers of the Urinary Bladder.
So Dug Lim, Yong Mee Cho, +5 authors, Ghilsuk Yoon.
J Korean Med Sci, 2015 Aug 05; 30(8). PMID: 26240484    Free PMC article.
In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer.
Michalina Janiszewska, Lin Liu, +12 authors, Kornelia Polyak.
Nat Genet, 2015 Aug 25; 47(10). PMID: 26301495    Free PMC article.
Highly Cited.
Proficiency testing in immunohistochemistry--experiences from Nordic Immunohistochemical Quality Control (NordiQC).
Mogens Vyberg, Søren Nielsen.
Virchows Arch, 2015 Aug 27; 468(1). PMID: 26306713    Free PMC article.
Breast cancer circulating biomarkers: advantages, drawbacks, and new insights.
Andrea Ravelli, James M Reuben, +13 authors, Solid Tumor Working Party of European Blood and Marrow Transplantation Society (EBMT).
Tumour Biol, 2015 Aug 27; 36(9). PMID: 26307395
Expression of DNA Damage Response Molecules PARP1, γH2AX, BRCA1, and BRCA2 Predicts Poor Survival of Breast Carcinoma Patients.
See-Hyoung Park, Sang Jae Noh, +9 authors, Kyu Yun Jang.
Transl Oncol, 2015 Aug 28; 8(4). PMID: 26310369    Free PMC article.
Monosomy of chromosome 17 in breast cancer during interpretation of HER2 gene amplification.
Matteo Brunelli, Alessia Nottegar, +27 authors, Franco Bonetti.
Am J Cancer Res, 2015 Sep 04; 5(7). PMID: 26328251    Free PMC article.
Comparison of Pathologic Response Evaluation Systems after Anthracycline with/without Taxane-Based Neoadjuvant Chemotherapy among Different Subtypes of Breast Cancers.
Hee Jin Lee, In Ah Park, +6 authors, Gyungyub Gong.
PLoS One, 2015 Sep 24; 10(9). PMID: 26394326    Free PMC article.
The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831.
Edith A Perez, Frederick L Baehner, +11 authors, Karla V Ballman.
Breast Cancer Res, 2015 Oct 03; 17(1). PMID: 26429296    Free PMC article.
High mobility group B1 and N1 (HMGB1 and HMGN1) are associated with tumor-infiltrating lymphocytes in HER2-positive breast cancers.
Hee Jin Lee, Joo Young Kim, +4 authors, Gyungyub Gong.
Virchows Arch, 2015 Oct 09; 467(6). PMID: 26445971
Assessment of a HER2 scoring system for colorectal cancer: results from a validation study.
Emanuele Valtorta, Cosimo Martino, +27 authors, Marcello Gambacorta.
Mod Pathol, 2015 Oct 10; 28(11). PMID: 26449765
Translating cancer genomes and transcriptomes for precision oncology.
Sameek Roychowdhury, Arul M Chinnaiyan.
CA Cancer J Clin, 2015 Nov 04; 66(1). PMID: 26528881    Free PMC article.
Targeted Therapies in HER2-Positive Breast Cancer - a Systematic Review.
Amelie Schramm, Nikolaus De Gregorio, +2 authors, Jens Huober.
Breast Care (Basel), 2015 Nov 12; 10(3). PMID: 26557822    Free PMC article.
Emerging prognostic markers related to mesenchymal characteristics of poorly differentiated breast cancers.
Manuel Scimeca, Chiara Antonacci, +3 authors, Elena Bonanno.
Tumour Biol, 2015 Nov 14; 37(4). PMID: 26563370
Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis.
Francesco Massari, Chiara Ciccarese, +20 authors, Matteo Brunelli.
Target Oncol, 2015 Nov 15; 11(3). PMID: 26566945
Comparison of targeted next-generation sequencing and Sanger sequencing for the detection of PIK3CA mutations in breast cancer.
Ruza Arsenic, Denise Treue, +4 authors, Jan Budczies.
BMC Clin Pathol, 2015 Nov 21; 15. PMID: 26587011    Free PMC article.
Immunohistochemical evaluation of ROCK activation in invasive breast cancer.
Chih-Yi Hsu, Zee-Fen Chang, Hsiao-Hui Lee.
BMC Cancer, 2015 Dec 03; 15. PMID: 26626121    Free PMC article.
Expression of CPEB4 in invasive ductal breast carcinoma and its prognostic significance.
Hao-Ting Sun, Xin Wen, +4 authors, Xiu-Ping Liu.
Onco Targets Ther, 2015 Dec 10; 8. PMID: 26648741    Free PMC article.
Correlation of clinicopathological outcomes with changes in IHC4 status after NACT in locally advanced breast cancers: do pre-NACT ER/PR status act as better prognosticators?
Sanjoy Chatterjee, Animesh Saha, +5 authors, Rosina Ahmed.
Breast Cancer (Dove Med Press), 2015 Dec 18; 7. PMID: 26677343    Free PMC article.
Low expression of BMPRIB indicates poor prognosis of breast cancer and is insensitive to taxane-anthracycline chemotherapy.
Kun Dai, Fengxia Qin, +6 authors, Yongjie Ma.
Oncotarget, 2015 Dec 20; 7(4). PMID: 26684357    Free PMC article.
Clinical verification of sensitivity to preoperative chemotherapy in cases of androgen receptor-expressing positive breast cancer.
Yuka Asano, Shinichiro Kashiwagi, +7 authors, Kosei Hirakawa.
Br J Cancer, 2016 Jan 13; 114(1). PMID: 26757422    Free PMC article.
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
Lyndsay N Harris, Nofisat Ismaila, +11 authors, American Society of Clinical Oncology.
J Clin Oncol, 2016 Feb 10; 34(10). PMID: 26858339    Free PMC article.
Highly Cited. Review.
Targeted therapies with companion diagnostics in the management of breast cancer: current perspectives.
Meagan B Myers.
Pharmgenomics Pers Med, 2016 Feb 10; 9. PMID: 26858530    Free PMC article.
An Appraisal of Proliferation and Apoptotic Markers in Papillary Thyroid Carcinoma: An Automated Analysis.
Monika Lamba Saini, Caroline Bouzin, Birgit Weynand, Etienne Marbaix.
PLoS One, 2016 Feb 11; 11(2). PMID: 26863116    Free PMC article.
Genetic alterations of triple negative breast cancer by targeted next-generation sequencing and correlation with tumor morphology.
Paul S Weisman, Charlotte K Y Ng, +11 authors, Hannah Y Wen.
Mod Pathol, 2016 Mar 05; 29(5). PMID: 26939876    Free PMC article.
Association Between Insulin Resistance and Luminal B Subtype Breast Cancer in Postmenopausal Women.
Sanggeun Nam, Seho Park, +3 authors, Seung Il Kim.
Medicine (Baltimore), 2016 Mar 06; 95(9). PMID: 26945364    Free PMC article.
Estrogen Receptor Expression Is Associated with DNA Repair Capacity in Breast Cancer.
Jaime Matta, Luisa Morales, +6 authors, Erick Suárez.
PLoS One, 2016 Apr 01; 11(3). PMID: 27032101    Free PMC article.
EZH2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic features.
Shuangping Guo, Xia Li, +4 authors, Zhe Wang.
Diagn Pathol, 2016 Apr 27; 11. PMID: 27113214    Free PMC article.
PD-L1 Expression in Lung Cancer.
Hui Yu, Theresa A Boyle, +2 authors, Fred R Hirsch.
J Thorac Oncol, 2016 Apr 28; 11(7). PMID: 27117833    Free PMC article.
Highly Cited. Review.
Differential expression of major histocompatibility complex class I in subtypes of breast cancer is associated with estrogen receptor and interferon signaling.
Hee Jin Lee, In Hye Song, +4 authors, Gyungyub Gong.
Oncotarget, 2016 Apr 29; 7(21). PMID: 27121061    Free PMC article.
Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment.
Keith T Schmidt, Cindy H Chau, Douglas K Price, William D Figg.
J Clin Pharmacol, 2016 May 21; 56(12). PMID: 27197880    Free PMC article.
Expression of FOXM1 and related proteins in breast cancer molecular subtypes.
Jeong-Ju Lee, Hee Jin Lee, +5 authors, Gyungyub Gong.
Int J Exp Pathol, 2016 Jun 10; 97(2). PMID: 27277416    Free PMC article.
Therapeutic effect of taxanes on metastatic breast cancer of various immunohistochemical subtypes.
Ippei Fukada, Kazuhiro Araki, +6 authors, Yoshinori Ito.
Oncol Lett, 2016 Jun 28; 12(1). PMID: 27347197    Free PMC article.
Predictive Value of Molecular Subtyping for Locoregional Recurrence in Early-Stage Breast Cancer with N1 without Postmastectomy Radiotherapy.
Ge Wen, Jin-Shan Zhang, +3 authors, Xun-Xing Guan.
J Breast Cancer, 2016 Jul 07; 19(2). PMID: 27382394    Free PMC article.
Agreement of Different Methods for Tissue Based Detection of HER2 Signal in Invasive Breast Cancer.
Gaurav Thakral, Andrew Wey, +2 authors, Christopher Lum.
Pathol Oncol Res, 2016 Jul 16; 23(1). PMID: 27417320
Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients.
Shaohua Zhang, Lei Li, +7 authors, Zefei Jiang.
BMC Cancer, 2016 Jul 28; 16. PMID: 27456503    Free PMC article.
The Efficacy of Trastuzumab in Animal Models of Breast Cancer: A Systematic Review and Meta-Analysis.
Jiarong Chen, Canhong Yang, +4 authors, Theodore C Hirst.
PLoS One, 2016 Jul 28; 11(7). PMID: 27463246    Free PMC article.
Systematic Review.
HER2 amplification level is not a prognostic factor for HER2-positive breast cancer with trastuzumab-based adjuvant treatment: a systematic review and meta-analysis.
Qian-Qian Xu, Bo Pan, +11 authors, Qiang Sun.
Oncotarget, 2016 Aug 28; 7(39). PMID: 27566580    Free PMC article.
Systematic Review.
HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials.
Michael F Press, Guido Sauter, +17 authors, Dennis J Slamon.
J Clin Oncol, 2016 Aug 31; 34(29). PMID: 27573653    Free PMC article.
Poorer Prognosis of Primary Signet-Ring Cell Carcinoma of the Breast Compared with Mucinous Carcinoma.
Xiufeng Wu, Zhenzhen Zhang, +8 authors, Jun Yan.
PLoS One, 2016 Sep 02; 11(9). PMID: 27583684    Free PMC article.
Musashi RNA-binding protein 2 regulates estrogen receptor 1 function in breast cancer.
M-H Kang, K J Jeong, +8 authors, Y-Y Park.
Oncogene, 2016 Sep 07; 36(12). PMID: 27593929
ERBB2 mutations associated with solid variant of high-grade invasive lobular breast carcinomas.
Gabrielle Deniziaut, Jean Christophe Tille, +9 authors, Anne Vincent-Salomon.
Oncotarget, 2016 Sep 08; 7(45). PMID: 27602491    Free PMC article.
Predictive Factors and Value of ypN+ after Neoadjuvant Chemotherapy in Clinically Lymph Node-Negative Breast Cancer.
Ippei Fukada, Kazuhiro Araki, +10 authors, Yoshinori Ito.
PLoS One, 2016 Sep 16; 11(9). PMID: 27631393    Free PMC article.
The analytical validation of the Oncotype DX Recurrence Score assay.
Frederick L Baehner.
Ecancermedicalscience, 2016 Oct 13; 10. PMID: 27729940    Free PMC article.
Systematic assessment of HER2/neu in gynecologic neoplasms, an institutional experience.
Jennifer S Woo, Sophia K Apple, +3 authors, Neda A Moatamed.
Diagn Pathol, 2016 Oct 25; 11(1). PMID: 27770810    Free PMC article.
Antigen Masking During Fixation and Embedding, Dissected.
Carla Rossana Scalia, Giovanna Boi, +7 authors, Giorgio Cattoretti.
J Histochem Cytochem, 2016 Nov 01; 65(1). PMID: 27798289    Free PMC article.
Clinical outcomes based on multigene profiling in metastatic breast cancer patients.
Reva K Basho, Debora de Melo Gagliato, +18 authors, Funda Meric-Bernstam.
Oncotarget, 2016 Nov 03; 7(47). PMID: 27806348    Free PMC article.
Differentially expressed miRNAs in triple negative breast cancer between African-American and non-Hispanic white women.
Bruna Sugita, Mandeep Gill, +16 authors, Luciane R Cavalli.
Oncotarget, 2016 Nov 05; 7(48). PMID: 27813494    Free PMC article.
HER2 mRNA transcript quantitation in breast cancer.
K Meehan, B Clynick, +3 authors, W N Erber.
Clin Transl Oncol, 2016 Nov 12; 19(5). PMID: 27837339
Prognostic significance of mucin expression profiles in breast carcinoma with signet ring cells: a clinicopathological study.
Ryuji Ohashi, Ayako Hayama, +4 authors, Zenya Naito.
Diagn Pathol, 2016 Nov 17; 11(1). PMID: 27846863    Free PMC article.
Application of the downgrade criteria to supplemental screening ultrasound for women with negative mammography but dense breasts.
Soo-Yeon Kim, Min Jung Kim, +2 authors, Eun-Kyung Kim.
Medicine (Baltimore), 2016 Nov 20; 95(44). PMID: 27858896    Free PMC article.
Comparison of immunophenotypes of primary breast carcinomas and multiple corresponding distant metastases: an autopsy study of 25 patients.
B Szekely, Zs I Nagy, +13 authors, J Kulka.
Clin Exp Metastasis, 2016 Nov 26; 34(1). PMID: 27885435
Prognostic significance of equivocal human epidermal growth factor receptor 2 results and clinical utility of alternative chromosome 17 genes in patients with invasive breast cancer: A cohort study.
Nour Sneige, Kenneth R Hess, +2 authors, Nuhad K Ibrahim.
Cancer, 2016 Nov 29; 123(7). PMID: 27893937    Free PMC article.
FISH testing of HER2 immunohistochemistry 1+ invasive breast cancer with unfavorable characteristics.
Stella Petroni, Lucia Caldarola, +4 authors, Giovanni Simone.
Oncol Lett, 2016 Dec 03; 12(5). PMID: 27899970    Free PMC article.
Detection of gene copy number alterations in DCIS and invasive breast cancer by QM-FISH.
Aifeng Pan, Yawei Zhou, +4 authors, Li Li.
Am J Transl Res, 2016 Dec 03; 8(11). PMID: 27904700    Free PMC article.
Generation, characterization, and maintenance of trastuzumab-resistant HER2+ breast cancer cell lines.
Sandra Zazo, Paula González-Alonso, +9 authors, Federico Rojo.
Am J Cancer Res, 2016 Dec 03; 6(11). PMID: 27904779    Free PMC article.
An mRNA Gene Expression-Based Signature to Identify FGFR1-Amplified Estrogen Receptor-Positive Breast Tumors.
Jingqin Luo, Shuzhen Liu, +11 authors, Matthew J Ellis.
J Mol Diagn, 2016 Dec 21; 19(1). PMID: 27993329    Free PMC article.
Patient-derived xenograft (PDX) models in basic and translational breast cancer research.
Lacey E Dobrolecki, Susie D Airhart, +29 authors, Michael T Lewis.
Cancer Metastasis Rev, 2016 Dec 28; 35(4). PMID: 28025748    Free PMC article.
Highly Cited. Review.
Clinical Pharmacogenetic Testing and Application: Laboratory Medicine Clinical Practice Guidelines.
Sollip Kim, Yeo Min Yun, +9 authors, Sail Chun.
Ann Lab Med, 2016 Dec 29; 37(2). PMID: 28029011    Free PMC article.
Heterogeneous expression of PD-L1 in pulmonary squamous cell carcinoma and adenocarcinoma: implications for assessment by small biopsy.
Thomas J Gniadek, Qing Kay Li, +3 authors, Edward Gabrielson.
Mod Pathol, 2017 Jan 07; 30(4). PMID: 28059094
HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.
Angela N Bartley, Mary Kay Washington, +12 authors, Jaffer A Ajani.
Am J Clin Pathol, 2017 Jan 13; 146(6). PMID: 28077399    Free PMC article.
Systematic Review.
Breast carcinoma subtypes show different patterns of metastatic behavior.
István Artúr Molnár, Béla Ákos Molnár, +11 authors, Anna-Mária Tőkés.
Virchows Arch, 2017 Jan 20; 470(3). PMID: 28101678
The neutrophil-to-lymphocyte ratio: a narrative review.
Sara Socorro Faria, Paulo César Fernandes, +5 authors, Patrice Forget.
Ecancermedicalscience, 2017 Jan 21; 10. PMID: 28105073    Free PMC article.
Highly Cited. Review.
Progressive APOBEC3B mRNA expression in distant breast cancer metastases.
Anieta M Sieuwerts, Willemijne A M E Schrijver, +6 authors, Carolien H M van Deurzen.
PLoS One, 2017 Feb 01; 12(1). PMID: 28141868    Free PMC article.
The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas.
Charlotte K Y Ng, Salvatore Piscuoglio, +12 authors, Jorge S Reis-Filho.
Clin Cancer Res, 2017 Feb 06; 23(14). PMID: 28153863    Free PMC article.
Highly Cited.
Glutaminase expression is a poor prognostic factor in node-positive triple-negative breast cancer patients with a high level of tumor-infiltrating lymphocytes.
Joo Young Kim, Sun-Hee Heo, +8 authors, Hee Jin Lee.
Virchows Arch, 2017 Feb 12; 470(4). PMID: 28185053
Treatment Outcomes and Clinicopathologic Characteristics of Triple-Negative Breast Cancer: A Report from Cancer Institute of Iran.
Mehrzad Mirzania, Seyed Reza Safaee, +3 authors, Reza Mehdizadeh.
Int J Hematol Oncol Stem Cell Res, 2017 Mar 14; 11(1). PMID: 28286613    Free PMC article.
Glucocorticoid receptor expression in 20 solid tumor types using immunohistochemistry assay.
Thaddeus S Block, Tiffany I Murphy, +2 authors, Frank J Lynch.
Cancer Manag Res, 2017 Mar 16; 9. PMID: 28293120    Free PMC article.
The scaffold protein p140Cap limits ERBB2-mediated breast cancer progression interfering with Rac GTPase-controlled circuitries.
Silvia Grasso, Jennifer Chapelle, +28 authors, Paola Defilippi.
Nat Commun, 2017 Mar 17; 8. PMID: 28300085    Free PMC article.
Performance of Mid-Treatment Breast Ultrasound and Axillary Ultrasound in Predicting Response to Neoadjuvant Chemotherapy by Breast Cancer Subtype.
Rosalind P Candelaria, Roland L Bassett, +5 authors, Wei Tse Yang.
Oncologist, 2017 Mar 21; 22(4). PMID: 28314842    Free PMC article.
Background Parenchymal Enhancement and Fibroglandular Tissue Proportion on Breast MRI: Correlation with Hormone Receptor Expression and Molecular Subtypes of Breast Cancer.
Mesut Öztürk, Ahmet Veysel Polat, +2 authors, Ayfer Kamalı Polat.
J Breast Health, 2017 Mar 24; 13(1). PMID: 28331765    Free PMC article.
Relevance of deep learning to facilitate the diagnosis of HER2 status in breast cancer.
Michel E Vandenberghe, Marietta L J Scott, +3 authors, Craig Barker.
Sci Rep, 2017 Apr 06; 7. PMID: 28378829    Free PMC article.
A Microfluidic Immunostaining System Enables Quality Assured and Standardized Immunohistochemical Biomarker Analysis.
Seyong Kwon, Chang Hyun Cho, +2 authors, Je-Kyun Park.
Sci Rep, 2017 Apr 06; 7. PMID: 28378835    Free PMC article.
Clinicopathologic study of invasive micropapillary carcinoma of the breast.
Shen-Li Tang, Ji-Qiao Yang, +4 authors, Qing Lv.
Oncotarget, 2017 Apr 19; 8(26). PMID: 28418916    Free PMC article.
Quantification of HER2 and estrogen receptor heterogeneity in breast cancer by single-molecule RNA fluorescence in situ hybridization.
Laura Annaratone, Michele Simonetti, +7 authors, Nicola Crosetto.
Oncotarget, 2017 Apr 21; 8(12). PMID: 28423635    Free PMC article.
CKS1BP7, a Pseudogene of CKS1B, is Co-Amplified with IGF1R in Breast Cancers.
Yansong Liu, Wei Wang, +3 authors, Li Li.
Pathol Oncol Res, 2017 Apr 26; 24(2). PMID: 28439706
Human epidermal growth factor receptor 2 expression is more important than Bacillus Calmette Guerin treatment in predicting the outcome of T1G3 bladder cancer.
Luigi Cormio, Francesca Sanguedolce, +7 authors, Pantaleo Bufo.
Oncotarget, 2017 Apr 28; 8(15). PMID: 28445991    Free PMC article.
Chromobox homolog 2 protein: A novel biomarker for predicting prognosis and Taxol sensitivity in patients with breast cancer.
Wang Yang Chen, Xian Yu Zhang, +3 authors, Da Pang.
Oncol Lett, 2017 Apr 30; 13(3). PMID: 28454227    Free PMC article.
Serum Metabolomic Profiles for Breast Cancer Diagnosis, Grading and Staging by Gas Chromatography-Mass Spectrometry.
Naila Irum Hadi, Qamar Jamal, +3 authors, Syed Ghulam Musharraf.
Sci Rep, 2017 May 13; 7(1). PMID: 28496143    Free PMC article.
Annexin A3 as a Prognostic Biomarker for Breast Cancer: A Retrospective Study.
Tao Zhou, Yong Li, +3 authors, Jiajie Shi.
Biomed Res Int, 2017 May 13; 2017. PMID: 28497041    Free PMC article.
Circulating tumor cell clusters-associated gene plakoglobin is a significant prognostic predictor in patients with breast cancer.
Wataru Goto, Shinichiro Kashiwagi, +9 authors, Masaichi Ohira.
Biomark Res, 2017 May 17; 5. PMID: 28507762    Free PMC article.
Invasive lobular carcinoma with extracellular mucin production-a novel pattern of lobular carcinomas of the breast. Clinico-pathological description of eight cases.
Gábor Cserni, Giuseppe Floris, +5 authors, Zsuzsanna Varga.
Virchows Arch, 2017 May 22; 471(1). PMID: 28528509
Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma: implications for translational research.
Sibylle Baechmann, Steffen Ormanns, +8 authors, Stefan Boeck.
BMC Cancer, 2017 May 28; 17(1). PMID: 28549417    Free PMC article.
Comparison of HER2 amplification status among breast cancer subgroups offers new insights in pathways of breast cancer progression.
Kathleen Lambein, Mieke Van Bockstal, +5 authors, Louis Libbrecht.
Virchows Arch, 2017 Jun 02; 471(5). PMID: 28567637
Correlation Between Preoperative Serum Carcinoembryonic Antigen Levels and Expression on Pancreatic and Rectal Cancer Tissue.
L S F Boogerd, F A Vuijk, +8 authors, Alexander L Vahrmeijer.
Biomark Cancer, 2017 Jun 06; 9. PMID: 28579847    Free PMC article.
Molecular characterization of breast cancer cell lines by clinical immunohistochemical markers.
André de Lima Mota, Adriane Feijo Evangelista, +4 authors, Marcia Maria Chiquitelli Marques.
Oncol Lett, 2017 Jun 08; 13(6). PMID: 28588725    Free PMC article.
Prognostic Significance of a Micropapillary Pattern in Pure Mucinous Carcinoma of the Breast: Comparative Analysis with Micropapillary Carcinoma.
Hyun-Jung Kim, Kyeongmee Park, +3 authors, Inseok Park.
J Pathol Transl Med, 2017 Jun 10; 51(4). PMID: 28597867    Free PMC article.
Age-associated prognostic and predictive biomarkers in patients with breast cancer.
Markéta Kolečková, Zdeněk Kolář, +2 authors, Radek Trojanec.
Oncol Lett, 2017 Jun 11; 13(6). PMID: 28599421    Free PMC article.
Cone-beam Breast Computed Tomography: CT Density Does Not Reflect Proliferation Potential and Receptor Expression of Breast Carcinoma.
Susanne Wienbeck, Uwe Fischer, +4 authors, Alexey Surov.
Transl Oncol, 2017 Jul 01; 10(4). PMID: 28666188    Free PMC article.
Impact of RASSF1A gene methylation on the metastatic axillary nodal status in breast cancer patients.
Eva Jezkova, Pavol Zubor, +6 authors, Jan Danko.
Oncol Lett, 2017 Jul 12; 14(1). PMID: 28693231    Free PMC article.
Variability in DNA Repair Capacity Levels among Molecular Breast Cancer Subtypes: Triple Negative Breast Cancer Shows Lowest Repair.
Jaime Matta, Carmen Ortiz, +2 authors, Erick Suárez.
Int J Mol Sci, 2017 Jul 15; 18(7). PMID: 28704967    Free PMC article.
Whole tumor section quantitative image analysis maximizes between-pathologists' reproducibility for clinical immunohistochemistry-based biomarkers.
Michael Barnes, Chukka Srinivas, +11 authors, Jim Ranger-Moore.
Lab Invest, 2017 Aug 15; 97(12). PMID: 28805805
Regional Variability in Percentage of Breast Cancers Reported as Positive for HER2 in California: Implications of Patient Demographics on Laboratory Benchmarks.
Chieh-Yu Lin, Eugene E Carneal, +5 authors, Kimberly H Allison.
Am J Clin Pathol, 2017 Aug 20; 148(3). PMID: 28821197    Free PMC article.
Breast cancer and Flammer syndrome: any symptoms in common for prediction, prevention and personalised medical approach?
Pavol Zubor, Alexandra Gondova, +4 authors, Olga Golubnitschaja.
EPMA J, 2017 Aug 22; 8(2). PMID: 28824738    Free PMC article.
Country and regional variations in purchase prices for essential cancer medications.
Raphael E Cuomo, Robert L Seidman, Tim K Mackey.
BMC Cancer, 2017 Aug 25; 17(1). PMID: 28836947    Free PMC article.
Validation of Immunohistochemical Assays for Integral Biomarkers in the NCI-MATCH EAY131 Clinical Trial.
Joseph D Khoury, Wei-Lien Wang, +5 authors, Stanley R Hamilton.
Clin Cancer Res, 2017 Aug 26; 24(3). PMID: 28839110    Free PMC article.
A novel treatment approach for retinoblastoma by targeting epithelial growth factor receptor expression with a shRNA lentiviral system.
Yong Chai, Juhua Xiao, +4 authors, Kai Huang.
Iran J Basic Med Sci, 2017 Aug 31; 20(7). PMID: 28852437    Free PMC article.
Separase is a marker for prognosis and mitotic activity in breast cancer.
Natalia Gurvits, Eliisa Löyttyniemi, +3 authors, Kati Talvinen.
Br J Cancer, 2017 Sep 01; 117(9). PMID: 28859055    Free PMC article.
BRCA1 protein expression and subcellular localization in primary breast cancer: Automated digital microscopy analysis of tissue microarrays.
Abeer M Mahmoud, Virgilia Macias, +4 authors, Garth H Rauscher.
PLoS One, 2017 Sep 02; 12(9). PMID: 28863181    Free PMC article.
High concordance of a closed-system, RT-qPCR breast cancer assay for HER2 mRNA, compared to clinically determined immunohistochemistry, fluorescence in situ hybridization, and quantitative immunofluorescence.
Brad E Wasserman, Daniel E Carvajal-Hausdorf, +8 authors, David L Rimm.
Lab Invest, 2017 Sep 12; 97(12). PMID: 28892092    Free PMC article.
Evaluation of Partial Breast Reirradiation with Intraoperative Radiotherapy after Prior Thoracic Radiation: A Single-Institution Report of Outcomes and Toxicity.
Christine Chin, Priya Jadeja, +4 authors, Eileen P Connolly.
Front Oncol, 2017 Sep 13; 7. PMID: 28894694    Free PMC article.
The early onset of peripheral neuropathy might be a robust predictor for time to treatment failure in patients with metastatic breast cancer receiving chemotherapy containing paclitaxel.
Ippei Fukada, Yoshinori Ito, +6 authors, Shinji Ohno.
PLoS One, 2017 Sep 13; 12(9). PMID: 28898275    Free PMC article.
Clinicopathological study of a dimorphic variant of breast carcinoma.
Nozomi Ueno, Hajime Kuroda, +5 authors, Yasuo Imai.
Breast Cancer, 2017 Oct 02; 25(2). PMID: 28965222    Free PMC article.
Discovery of NKCC1 as a potential therapeutic target to inhibit hepatocellular carcinoma cell growth and metastasis.
Yaya Zhou, Wei Sun, +10 authors, Ying Jiang.
Oncotarget, 2017 Oct 17; 8(39). PMID: 29029515    Free PMC article.
Overview on Patient Centricity in Cancer Care.
Šarunas Narbutas, Kristina York, +5 authors, Andras Inotai.
Front Pharmacol, 2017 Oct 21; 8. PMID: 29051734    Free PMC article.
Canine invasive mammary carcinomas as models of human breast cancer. Part 2: immunophenotypes and prognostic significance.
Jérôme Abadie, Frédérique Nguyen, +8 authors, Mario Campone.
Breast Cancer Res Treat, 2017 Oct 25; 167(2). PMID: 29063312    Free PMC article.
Canine invasive mammary carcinomas as models of human breast cancer. Part 1: natural history and prognostic factors.
Frédérique Nguyen, Laura Peña, +6 authors, Jérôme Abadie.
Breast Cancer Res Treat, 2017 Nov 01; 167(3). PMID: 29086231    Free PMC article.
Downregulation of TAP1 and TAP2 in early stage breast cancer.
Andrea M Henle, Aziza Nassar, +2 authors, Keith L Knutson.
PLoS One, 2017 Nov 02; 12(11). PMID: 29091951    Free PMC article.
Comparative Evaluation of Anti-HER2 Affibody Molecules Labeled with 64Cu Using NOTA and NODAGA.
Vladimir Tolmachev, Cheng-Bin Yim, +6 authors, Anna Orlova.
Contrast Media Mol Imaging, 2017 Nov 04; 2017. PMID: 29097939    Free PMC article.
A Retrospective Analysis of Clinical Utility of AJCC 8th Edition Cancer Staging System for Breast Cancer.
Hui Hu, Wei Wei, +2 authors, Yinhua Liu.
World J Oncol, 2017 Nov 18; 8(3). PMID: 29147438    Free PMC article.
MiR-1268b confers chemosensitivity in breast cancer by targeting ERBB2-mediated PI3K-AKT pathway.
Wen-Jie Zhu, Xu Chen, +3 authors, Peng Gao.
Oncotarget, 2017 Nov 23; 8(52). PMID: 29163776    Free PMC article.
Optimizing fresh specimen staining for rapid identification of tumor biomarkers during surgery.
Connor W Barth, Jasmin M Schaefer, +2 authors, Summer L Gibbs.
Theranostics, 2017 Dec 01; 7(19). PMID: 29187899    Free PMC article.
Role of HER-2/neu in Premalignant and Malignant Lesions of Uterine Cervix.
Swasti Bajpai, Seema Awasthi, +3 authors, Faiyaz Ahmad.
J Clin Diagn Res, 2017 Dec 07; 11(9). PMID: 29207712    Free PMC article.
Clinical and Epidemiological Profile of Breast Cancer in Mexico: Results of the Seguro Popular.
Nancy Reynoso-Noverón, Cynthia Villarreal-Garza, +9 authors, Alejandro Mohar.
J Glob Oncol, 2017 Dec 16; 3(6). PMID: 29244990    Free PMC article.
Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) to select the optimal patients for matched therapy?
Young Kwang Chae, Ayush Arya, +9 authors, Francis Giles.
Oncotarget, 2017 Dec 17; 8(59). PMID: 29246028    Free PMC article.
Protein biomarkers for subtyping breast cancer and implications for future research.
Claudius Mueller, Amanda Haymond, +2 authors, Virginia Espina.
Expert Rev Proteomics, 2017 Dec 23; 15(2). PMID: 29271260    Free PMC article.
Prognostic parameters of luminal A and luminal B intrinsic breast cancer subtypes of Pakistani patients.
Atif Ali Hashmi, Saher Aijaz, +8 authors, Amir Khan.
World J Surg Oncol, 2018 Jan 03; 16(1). PMID: 29291744    Free PMC article.
Predictive and prognostic value of sphingosine kinase 1 expression in patients with invasive ductal carcinoma of the breast.
Sung-Im Do, Hyun-Soo Kim, +5 authors, Jin Hee Sohn.
Am J Transl Res, 2018 Jan 10; 9(12). PMID: 29312521    Free PMC article.
Comprehensive molecular profiling of advanced/metastatic olfactory neuroblastomas.
Jasmina Topcagic, Rebecca Feldman, +3 authors, Semir Vranic.
PLoS One, 2018 Jan 13; 13(1). PMID: 29324814    Free PMC article.
High expression of PU.1 is associated with Her-2 and shorter survival in patients with breast cancer.
Jing Lin, Wei Liu, +7 authors, Lihong Wang.
Oncol Lett, 2018 Jan 19; 14(6). PMID: 29344265    Free PMC article.
Expansion of tumor-infiltrating lymphocytes and their potential for application as adoptive cell transfer therapy in human breast cancer.
Hee Jin Lee, Young-Ae Kim, +16 authors, Gyungyub Gong.
Oncotarget, 2018 Jan 27; 8(69). PMID: 29371915    Free PMC article.
Contrast-enhanced MRI after neoadjuvant chemotherapy of breast cancer: lesion-to-background parenchymal signal enhancement ratio for discriminating pathological complete response from minimal residual tumour.
Soo-Yeon Kim, Nariya Cho, +8 authors, Woo Kyung Moon.
Eur Radiol, 2018 Jan 31; 28(7). PMID: 29380033
Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ.
Marie Beguinot, Marie-Melanie Dauplat, +5 authors, Nina Radosevic-Robin.
BMC Cancer, 2018 Feb 06; 18(1). PMID: 29394917    Free PMC article.
PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics.
Margarita Udall, Maria Rizzo, +4 authors, Eric Faulkner.
Diagn Pathol, 2018 Feb 11; 13(1). PMID: 29426340    Free PMC article.
Highly Cited. Systematic Review.
Improving accuracy of breast cancer biomarker testing in India.
Tanuja Shet.
Indian J Med Res, 2018 Feb 13; 146(4). PMID: 29434058    Free PMC article.
Clinical significance of quantitative HER2 gene amplification as related to its predictive value in breast cancer patients in neoadjuvant setting.
Ziping Wu, Shuguang Xu, +8 authors, Jinsong Lu.
Onco Targets Ther, 2018 Mar 03; 11. PMID: 29497312    Free PMC article.
Prognostic implications of HER2 heterogeneity in gastric cancer.
Shigenobu Motoshima, Koji Yonemoto, +2 authors, Rin Yamaguchi.
Oncotarget, 2018 Mar 07; 9(10). PMID: 29507688    Free PMC article.
The role of programmed death ligand-1 and tumor-infiltrating lymphocytes in breast cancer overexpressing HER2 gene.
Yanchun Li, Mateusz Opyrchal, +4 authors, Thaer Khoury.
Breast Cancer Res Treat, 2018 Mar 11; 170(2). PMID: 29524062    Free PMC article.
Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes.
Valeriy Domenyuk, Zoran Gatalica, +26 authors, David Spetzler.
Nat Commun, 2018 Mar 25; 9(1). PMID: 29572535    Free PMC article.
Mammographic Breast Density and Breast Cancer Molecular Subtypes: The Kenyan-African Aspect.
Asim Jamal Shaikh, Maeve Mullooly, +6 authors, Gretchen L Gierach.
Biomed Res Int, 2018 Apr 03; 2018. PMID: 29607324    Free PMC article.
Altered monocyte differentiation and macrophage polarization patterns in patients with breast cancer.
Chih-Hsing Hung, Fang-Ming Chen, +5 authors, Ming-Feng Hou.
BMC Cancer, 2018 Apr 05; 18(1). PMID: 29614988    Free PMC article.
MRI-based response patterns during neoadjuvant chemotherapy can predict pathological (complete) response in patients with breast cancer.
Briete Goorts, Kelly M A Dreuning, +5 authors, Marjolein L Smidt.
Breast Cancer Res, 2018 Apr 20; 20(1). PMID: 29669584    Free PMC article.
Genetic alterations analysis in prognostic stratified groups identified TP53 and ARID1A as poor clinical performance markers in intrahepatic cholangiocarcinoma.
Michele Simbolo, Caterina Vicentini, +15 authors, Aldo Scarpa.
Sci Rep, 2018 May 10; 8(1). PMID: 29740198    Free PMC article.
The Association between Molecular Subtypes of Breast Cancer with Histological Grade and Lymph Node Metastases in Indonesian Woman
Yunita Setyawati, Yeni Rahmawati, +2 authors, Dewajani Purnomosari.
Asian Pac J Cancer Prev, 2018 May 29; 19(5). PMID: 29801411    Free PMC article.
Clinical significance of androgen receptor expression in triple negative breast cancer-an immunohistochemistry study.
Ya-Xuan Liu, Ke-Jing Zhang, Li-Li Tang.
Oncol Lett, 2018 May 31; 15(6). PMID: 29844843    Free PMC article.
Identifying an early treatment window for predicting breast cancer response to neoadjuvant chemotherapy using immunohistopathology and hemoglobin parameters.
Quing Zhu, Susan Tannenbaum, +10 authors, Kert Sabbath.
Breast Cancer Res, 2018 Jun 15; 20(1). PMID: 29898762    Free PMC article.
High Densities of Tumor-Associated Plasma Cells Predict Improved Prognosis in Triple Negative Breast Cancer.
Joe Yeong, Jeffrey Chun Tatt Lim, +10 authors, Jabed Iqbal.
Front Immunol, 2018 Jun 15; 9. PMID: 29899747    Free PMC article.
LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases.
Amanda E D Van Swearingen, Marni B Siegel, +21 authors, Carey K Anders.
Breast Cancer Res Treat, 2018 Jun 26; 171(3). PMID: 29938395    Free PMC article.
Outcome of inflammatory breast cancer in Moroccan patients: clinical, molecular and pathological characteristics of 219 cases from the National Oncology Institute (INO).
Meriem Slaoui, Abdou Azaque Zoure, +4 authors, Mariam Amrani.
BMC Cancer, 2018 Jul 07; 18(1). PMID: 29976157    Free PMC article.
The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers.
Michael T Barrett, Elizabeth Lenkiewicz, +10 authors, Barbara A Pockaj.
Breast Cancer Res, 2018 Jul 13; 20(1). PMID: 29996881    Free PMC article.
Associations of angiogenesis-related proteins with specific prognostic factors, breast cancer subtypes and survival outcome in early-stage breast cancer patients. A Hellenic Cooperative Oncology Group (HeCOG) trial.
Anna Goussia, Nafsika Simou, +24 authors, Anna Batistatou.
PLoS One, 2018 Aug 01; 13(7). PMID: 30063723    Free PMC article.
Clinicopathologic features of invasive metaplastic and micropapillary breast carcinoma: comparison with invasive ductal carcinoma of breast.
Atif Ali Hashmi, Saher Aijaz, +8 authors, Amir Khan.
BMC Res Notes, 2018 Aug 02; 11(1). PMID: 30064485    Free PMC article.
Subtyping Of Triple Negative Breast Carcinoma On The Basis Of RTK Expression.
Harald Hessel, Manuela Poignée-Heger, +6 authors, Thomas Kirchner.
J Cancer, 2018 Aug 09; 9(15). PMID: 30087699    Free PMC article.
APOBEC3B gene expression as a novel predictive factor for pathological complete response to neoadjuvant chemotherapy in breast cancer.
Yoshitaka Fujiki, Yutaka Yamamoto, +5 authors, Hirotaka Iwase.
Oncotarget, 2018 Aug 11; 9(55). PMID: 30093965    Free PMC article.
Clinical and prognostic profile of Her2neu positive (non-luminal) intrinsic breast cancer subtype: comparison with Her2neu positive luminal breast cancers.
Atif Ali Hashmi, Raeesa Mahboob, +7 authors, Muhammad Muzzammil Edhi.
BMC Res Notes, 2018 Aug 15; 11(1). PMID: 30103802    Free PMC article.
Laminin 332 expression and prognosis in breast cancer.
Philip M Carpenter, Argyrios Ziogas, +3 authors, Hoda Anton-Culver.
Hum Pathol, 2018 Aug 21; 82. PMID: 30125583    Free PMC article.
Decreased methylation in the SNAI2 and ADAM23 genes associated with de-differentiation and haematogenous dissemination in breast cancers.
Lenka Kalinkova, Iveta Zmetakova, +6 authors, Ivana Fridrichova.
BMC Cancer, 2018 Sep 08; 18(1). PMID: 30189837    Free PMC article.
Immunoexpression of claudins 4 and 7 among invasive breast carcinoma subtypes: A large diagnostic study using tissue microarray.
Angela Flávia Logullo, Fatima Solange Pasini, +3 authors, Maria Mitzi Brentani.
Mol Clin Oncol, 2018 Sep 15; 9(4). PMID: 30214726    Free PMC article.
Intravoxel incoherent motion magnetic resonance imaging for breast cancer: A comparison with benign lesions and evaluation of heterogeneity in different tumor regions with prognostic factors and molecular classification.
Ming Zhao, Kuang Fu, +6 authors, Jiawei Tian.
Oncol Lett, 2018 Sep 27; 16(4). PMID: 30250578    Free PMC article.
The Prognostic Impact of Synchronous Ipsilateral Multiple Breast Cancer: Survival Outcomes according to the Eighth American Joint Committee on Cancer Staging and Molecular Subtype.
Jinah Chu, Hyunsik Bae, +3 authors, Eun Yoon Cho.
J Pathol Transl Med, 2018 Oct 24; 52(6). PMID: 30347971    Free PMC article.
Quantitative assessment of metabolic tumor burden in molecular subtypes of primary breast cancer with FDG PET/CT.
Wei Chen, Lei Zhu, +3 authors, Ping Wang.
Diagn Interv Radiol, 2018 Nov 09; 24(6). PMID: 30406761    Free PMC article.
Significance of intrinsic breast cancer subtypes on the long-term prognosis after neoadjuvant chemotherapy.
Wataru Goto, Shinichiro Kashiwagi, +7 authors, Masaichi Ohira.
J Transl Med, 2018 Nov 11; 16(1). PMID: 30413161    Free PMC article.
Predictive value of lymphocyte-to-monocyte ratio in the preoperative setting for progression of patients with breast cancer.
Wataru Goto, Shinichiro Kashiwagi, +8 authors, Masaichi Ohira.
BMC Cancer, 2018 Nov 21; 18(1). PMID: 30453914    Free PMC article.
Y-Box binding protein 1 expression in breast cancer and its correlation with hormone receptors and other prognostic markers.
Taruna Bansal, Nadeem Tanveer, +2 authors, Navneet Kaur.
J Lab Physicians, 2018 Dec 01; 10(4). PMID: 30498315    Free PMC article.
Correlation of Serum Levels of Urokinase Activation Plasminogen (uPA) and Its Inhibitor (PAI-1) with Hormonal and HER-2 Status in the Early Invasive Breast Cancer.
Sadat Pusina.
Med Arch, 2018 Dec 14; 72(5). PMID: 30524164    Free PMC article.
An Introduction to Starting a Biobank.
Mitra D Harati, Ryan R Williams, +3 authors, William H Yong.
Methods Mol Biol, 2018 Dec 13; 1897. PMID: 30539430    Free PMC article.
Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study.
Sara A Hurvitz, Miguel Martin, +18 authors, Dennis Slamon.
J Clin Oncol, 2019 Jun 04; 37(25). PMID: 31157583    Free PMC article.
Homologous recombination DNA repair defects in PALB2-associated breast cancers.
Anqi Li, Felipe C Geyer, +36 authors, Jorge S Reis-Filho.
NPJ Breast Cancer, 2019 Aug 21; 5. PMID: 31428676    Free PMC article.
Validation of Residual Cancer Burden as Prognostic Factor for Breast Cancer Patients After Neoadjuvant Therapy.
Hannah Deborah Müller, Florian Posch, +9 authors, Marija Balic.
Ann Surg Oncol, 2019 Aug 28; 26(13). PMID: 31452052    Free PMC article.
Elimination of Osteosarcoma by Necroptosis with Graphene Oxide-Associated Anti-HER2 Antibodies.
Hongmei Xiao, Peter E Jensen, Xinjian Chen.
Int J Mol Sci, 2019 Sep 08; 20(18). PMID: 31491952    Free PMC article.
Tumor-infiltrating lymphocytes and CD8+ T cells predict survival of triple-negative breast cancer.
H Vihervuori, T A Autere, +5 authors, P Kronqvist.
J Cancer Res Clin Oncol, 2019 Sep 29; 145(12). PMID: 31562550    Free PMC article.
Cytoplasmic Her2/neu Immunohistochemical Staining in Breast Cancer; From a Molecular Point of View.
Akbar Safaei, Ahmad Monabati, Maral Mokhtari, Mehdi Montazer.
Iran J Pathol, 2019 Oct 05; 14(3). PMID: 31583007    Free PMC article.
Clinical significance of evaluating hormone receptor and HER2 protein using cell block against metastatic breast cancer: a multi-institutional study.
Akira Matsui, Yuya Murata, +16 authors, Rieko Nishimura.
Oncotarget, 2019 Oct 18; 10(55). PMID: 31620243    Free PMC article.
Correlation between the Expression of PD-L1 and Clinicopathological Parameters in Triple Negative Breast Cancer Patients.
Rabia Doğukan, Ramazan Uçak, +3 authors, Fevziye Kabukcuoğlu.
Eur J Breast Health, 2019 Oct 18; 15(4). PMID: 31620682    Free PMC article.
Suboptimal concordance in testing and retesting results of triple-negative breast carcinoma cases among laboratories: one institution experience.
Jose De Jesus, Marilin Rosa.
Cancer Cell Int, 2019 Oct 22; 19. PMID: 31632197    Free PMC article.
Integrated copy number and miRNA expression analysis in triple negative breast cancer of Latin American patients.
Bruna M Sugita, Silma R Pereira, +14 authors, Luciane R Cavalli.
Oncotarget, 2019 Nov 07; 10(58). PMID: 31692930    Free PMC article.
Proposal for a Histological Staging System of Mammary Carcinomas in Dogs and Cats. Part 1: Canine Mammary Carcinomas.
Florian Chocteau, Jérôme Abadie, Delphine Loussouarn, Frédérique Nguyen.
Front Vet Sci, 2019 Dec 04; 6. PMID: 31788485    Free PMC article.
Storage Conditions and Immunoreactivity of Breast Cancer Subtyping Markers in Tissue Microarray Sections.
Angela R Omilian, Gary R Zirpoli, +8 authors, Wiam Bshara.
Appl Immunohistochem Mol Morphol, 2019 Jun 18; 28(4). PMID: 31205070    Free PMC article.
Somatic genetic aberrations in gallbladder cancer: comparison between Chinese and US patients.
Pingzhou Yang, Milind Javle, +13 authors, Xu Che.
Hepatobiliary Surg Nutr, 2020 Jan 14; 8(6). PMID: 31929987    Free PMC article.
Low nuclear zinc finger and BTB domain containing 7A expression is an independent prognostic factor for recurrence-free survival in invasive ductal carcinoma of the breast.
Yuil Kim, Hyun-Soo Kim, Sung-Im Do.
Int J Clin Exp Pathol, 2018 Apr 01; 11(4). PMID: 31938331    Free PMC article.
Concordance of immunohistochemistry and fluorescence in situ hybridization for assessment of HER2 status in breast cancer patients in Xinjiang autonomous region, China.
Bing Zhao, Yu Wang, Hang Xu.
Int J Clin Exp Pathol, 2017 Oct 01; 10(10). PMID: 31966383    Free PMC article.
Nomograms for predicting the likelihood of non-sentinel lymph node metastases in breast cancer patients with a positive sentinel node biopsy.
Lihua Zheng, Feng Liu, +2 authors, Yunjiang Liu.
Medicine (Baltimore), 2019 Dec 27; 98(52). PMID: 31876745    Free PMC article.
Oncologic outcomes after immediate breast reconstruction following mastectomy: comparison of implant and flap using propensity score matching.
Jeong Hyun Ha, Ki Yong Hong, +7 authors, Ung Sik Jin.
BMC Cancer, 2020 Feb 01; 20(1). PMID: 32000718    Free PMC article.
Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer.
Lillian M Smyth, Sarina A Piha-Paul, +44 authors, David M Hyman.
Cancer Discov, 2019 Dec 07; 10(2). PMID: 31806627    Free PMC article.
Structural Studies of Epithelial Mesenchymal Transition Breast Tissues.
S N Mohd Sobri, S F Abdul Sani, +5 authors, D A Bradley.
Sci Rep, 2020 Feb 08; 10(1). PMID: 32029810    Free PMC article.
Retained or altered expression of major histocompatibility complex class I in patient-derived xenograft models in breast cancer.
In Hye Song, Young-Ae Kim, +6 authors, Hee Jin Lee.
Immunol Res, 2020 Jan 05; 67(6). PMID: 31900802
Quantitative analysis of HER2 mRNA expression by RNA in situ hybridization in canine mammary gland tumors: Comparison with immunohistochemistry analysis.
Byung-Joon Seung, Seung-Hee Cho, +2 authors, Jung-Hyang Sur.
PLoS One, 2020 Feb 15; 15(2). PMID: 32059046    Free PMC article.
Prognostic Utility of Cyclin D1 in Invasive Breast Carcinoma.
Tamanna Parvin, Chhanda Das, +2 authors, Madhumita Mukhopadhyay.
Indian J Surg Oncol, 2019 Apr 06; 10(1). PMID: 30948894    Free PMC article.
Mismatch Repair Deficiency Drives Durable Complete Remission by Targeting Programmed Death Receptor 1 in a Metastatic Luminal Breast Cancer Patient.
Carlo Fremd, Mario Hlevnjak, +13 authors, Andreas Schneeweiss.
Breast Care (Basel), 2019 Apr 26; 14(1). PMID: 31019444    Free PMC article.
Predictive and prognostic value of PDL1 protein expression in breast cancer patients in neoadjuvant setting.
Ziping Wu, Lei Zhang, +7 authors, Jinsong Lu.
Cancer Biol Ther, 2019 Mar 15; 20(6). PMID: 30866717    Free PMC article.
Invasive micropapillary carcinoma of the breast had no difference in prognosis compared with invasive ductal carcinoma: a propensity-matched analysis.
Shuang Hao, Yuan-Yuan Zhao, +4 authors, Zhi-Ming Shao.
Sci Rep, 2019 Jan 24; 9(1). PMID: 30670771    Free PMC article.
Molecular alterations and PD-L1 expression in non-ampullary duodenal adenocarcinoma: Associations among clinicopathological, immunophenotypic and molecular features.
Jiro Watari, Seiichiro Mitani, +16 authors, Hiroto Miwa.
Sci Rep, 2019 Jul 22; 9(1). PMID: 31324814    Free PMC article.
Therapeutic options for mucinous ovarian carcinoma.
Kylie L Gorringe, Dane Cheasley, +37 authors, Clare L Scott.
Gynecol Oncol, 2020 Jan 07; 156(3). PMID: 31902686    Free PMC article.
High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance).
Saranya Chumsri, Jeff Sperinde, +13 authors, Edith A Perez.
Clin Cancer Res, 2018 Mar 14; 24(13). PMID: 29530935    Free PMC article.
The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers.
Pedram Razavi, Matthew T Chang, +42 authors, José Baselga.
Cancer Cell, 2018 Sep 12; 34(3). PMID: 30205045    Free PMC article.
Highly Cited.
Community clinical practice patterns and mortality in patients with intermediate oncotype DX recurrence scores: Who benefits from chemotherapy?
Abiola F Ibraheem, David J Press, Olufunmilayo I Olopade, Dezheng Huo.
Cancer, 2018 Nov 06; 125(2). PMID: 30387876    Free PMC article.
Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines.
Michael F Press, Jose A Seoane, +14 authors, Dennis J Slamon.
JAMA Oncol, 2018 Dec 07; 5(3). PMID: 30520947    Free PMC article.
An Aptamer-Based Probe for Molecular Subtyping of Breast Cancer.
Mei Liu, Zhifei Wang, +6 authors, Nongyue He.
Theranostics, 2018 Dec 18; 8(20). PMID: 30555580    Free PMC article.
Prognostic value of CD8 + PD-1+ immune infiltrates and PDCD1 gene expression in triple negative breast cancer.
Joe Yeong, Jeffrey Chun Tatt Lim, +15 authors, Puay Hoon Tan.
J Immunother Cancer, 2019 Feb 08; 7(1). PMID: 30728081    Free PMC article.
A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients.
Begoña Pineda, Angel Diaz-Lagares, +7 authors, Pilar Eroles.
Clin Epigenetics, 2019 Feb 23; 11(1). PMID: 30786922    Free PMC article.
Prognostic and Predictive Immunohistochemistry-Based Biomarkers in Cancer and Immunotherapy.
Emanuelle M Rizk, Robyn D Gartrell, +4 authors, Yvonne M Saenger.
Hematol Oncol Clin North Am, 2019 Mar 06; 33(2). PMID: 30833001    Free PMC article.
An Ad Hoc Random Initialization Deep Neural Network Architecture for Discriminating Malignant Breast Cancer Lesions in Mammographic Images.
Andrea Duggento, Marco Aiello, +5 authors, Nicola Toschi.
Contrast Media Mol Imaging, 2019 Jun 30; 2019. PMID: 31249497    Free PMC article.
Detection of lymph node metastasis in lung cancer patients using a one-step nucleic acid amplification assay: a single-centre prospective study.
María Escalante Pérez, María Teresa Hermida Romero, +4 authors, Ángel Concha López.
J Transl Med, 2019 Jul 25; 17(1). PMID: 31331335    Free PMC article.
Cell-specific biomarkers and targeted biopharmaceuticals for breast cancer treatment.
Mei Liu, Zhiyang Li, +5 authors, Zhifei Wang.
Cell Prolif, 2016 Jun 18; 49(4). PMID: 27312135    Free PMC article.
Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumab-resistance: a retrospective study of a Chinese population.
Fan Yang, Xiang Huang, +17 authors, Zefei Jiang.
BMC Cancer, 2020 Apr 01; 20(1). PMID: 32223744    Free PMC article.
Six Months vs. 12 Months of Adjuvant Trastuzumab Among Women With HER2-Positive Early-Stage Breast Cancer: A Meta-Analysis of Randomized Controlled Trials.
Huan Deng, Xianghui Du, Li Wang, Ming Chen.
Front Oncol, 2020 Apr 09; 10. PMID: 32266131    Free PMC article.
Systematic Review.
Overexpression of HER2/HER3 and clinical feature of ovarian cancer.
Ye Won Chung, Seongmin Kim, +4 authors, Jae Yun Song.
J Gynecol Oncol, 2019 Jul 23; 30(5). PMID: 31328457    Free PMC article.
Loss of Y-Chromosome during Male Breast Carcinogenesis.
Marie Colombe Agahozo, Mieke A M Timmermans, +7 authors, Carolien H M van Deurzen.
Cancers (Basel), 2020 Mar 19; 12(3). PMID: 32182822    Free PMC article.
Biomarker validation and testing.
Daniel F Hayes.
Mol Oncol, 2014 Dec 03; 9(5). PMID: 25458054    Free PMC article.
Risk stratification of ER-positive breast cancer patients: A multi-institutional validation and outcome study of the Rochester Modified Magee algorithm (RoMMa) and prediction of an Oncotype DX® recurrence score <26.
Bradley M Turner, Mary Ann Gimenez-Sanders, +6 authors, David G Hicks.
Cancer Med, 2019 Jun 15; 8(9). PMID: 31199586    Free PMC article.
Subtype-Guided 18 F-FDG PET/CT in Tailoring Axillary Surgery Among Patients with Node-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy: A Feasibility Study.
Siyu Wu, Yujie Wang, +8 authors, Guangyu Liu.
Oncologist, 2020 Apr 17; 25(4). PMID: 32297448    Free PMC article.
Imaging features of triple-negative breast cancers according to androgen receptor status.
Rosalind P Candelaria, Beatriz E Adrada, +13 authors, Wei Tse Yang.
Eur J Radiol, 2019 Apr 22; 114. PMID: 31005169    Free PMC article.
Evaluation of human epidermal growth factor receptor 2 status of breast cancer using preoperative multidetector computed tomography with deep learning and handcrafted radiomics features.
Xiaojun Yang, Lei Wu, +12 authors, Changhong Liang.
Chin J Cancer Res, 2020 May 16; 32(2). PMID: 32410795    Free PMC article.
Prior to Initiation of Chemotherapy, Can We Predict Breast Tumor Response? Deep Learning Convolutional Neural Networks Approach Using a Breast MRI Tumor Dataset.
Richard Ha, Christine Chin, +7 authors, Sachin Jambawalikar.
J Digit Imaging, 2018 Oct 27; 32(5). PMID: 30361936    Free PMC article.
Influence of Androgen Receptor on the Prognosis of Breast Cancer.
Ki-Tae Hwang, Young A Kim, +5 authors, Jin Hyun Park.
J Clin Med, 2020 Apr 16; 9(4). PMID: 32290220    Free PMC article.
Values of 5mC, 5hmC, and TET2 for identifying the presence and progression of breast precancerous lesion.
Zijing Zhang, Yiting Jin, +8 authors, Qiang Zou.
J Clin Lab Anal, 2019 Dec 24; 34(5). PMID: 31867779    Free PMC article.
Intratumoral Estrogen Receptor Heterogeneity of Expression in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer as Evaluated by a Brightfield Multiplex Assay.
Shinobu Masuda, Hiroaki Nitta, +3 authors, Eslie Dennis.
J Histochem Cytochem, 2019 Jun 12; 67(8). PMID: 31184528    Free PMC article.
A prognostic model based on cell-cycle control predicts outcome of breast cancer patients.
Heli Repo, Eliisa Löyttyniemi, +4 authors, Pauliina Kronqvist.
BMC Cancer, 2020 Jun 18; 20(1). PMID: 32546141    Free PMC article.
Targeting human epidermal growth factor receptor 2 (HER2) in gynecologic malignancies.
Britt K Erickson, Burak Zeybek, Alessandro D Santin, Amanda N Fader.
Curr Opin Obstet Gynecol, 2019 Dec 14; 32(1). PMID: 31833974    Free PMC article.
Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors.
Hua Guo, Qingqing Ding, +12 authors, Lei Huo.
Breast Cancer Res, 2020 Jun 25; 22(1). PMID: 32576238    Free PMC article.
Impact of Pre-Analytical Conditions on the Antigenicity of Lung Markers: ALK and MET.
Rachel Miller, Trish Thorne-Nuzzo, +3 authors, June Clements.
Appl Immunohistochem Mol Morphol, 2019 Feb 07; 28(5). PMID: 30724750    Free PMC article.
Shared-patient physician networks and their impact on the uptake of genomic testing in breast cancer.
Jason Rotter, Lauren Wilson, +2 authors, Michaela Dinan.
Breast Cancer Res Treat, 2019 Apr 28; 176(2). PMID: 31028607    Free PMC article.
Prognostic significance of preoperative albumin to fibrinogen ratio associated nomograms in patients with breast invasive ductal carcinoma.
Lihua Zheng, Yaheng Zhao, +5 authors, Yunjiang Liu.
Medicine (Baltimore), 2020 Jun 27; 99(26). PMID: 32590741    Free PMC article.
Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer.
Corinna Keup, Markus Storbeck, +7 authors, Sabine Kasimir-Bauer.
Cancers (Basel), 2019 Feb 20; 11(2). PMID: 30781720    Free PMC article.
C Kent Osborne, Rachel Schiff, Mothamar Rimawi.
Trans Am Clin Climatol Assoc, 2020 Jul 18; 131. PMID: 32675852    Free PMC article.
Characterizations of Cancer Gene Mutations in Chinese Metastatic Breast Cancer Patients.
Zhonghua Tao, Ting Li, +12 authors, Xichun Hu.
Front Oncol, 2020 Jul 23; 10. PMID: 32695676    Free PMC article.
Unique genomic and neoepitope landscapes across tumors: a study across time, tissues, and space within a single lynch syndrome patient.
Tanya N Phung, Elizabeth Lenkiewicz, +5 authors, Michael T Barrett.
Sci Rep, 2020 Jul 24; 10(1). PMID: 32699259    Free PMC article.
Developing precision medicine in a global world.
Eric H Rubin, Jeffrey D Allen, Jan A Nowak, Susan E Bates.
Clin Cancer Res, 2014 Mar 19; 20(6). PMID: 24634465    Free PMC article.
Characterizing functional consequences of DNA copy number alterations in breast and ovarian tumors by spaceMap.
Christopher J Conley, Umut Ozbek, Pei Wang, Jie Peng.
J Genet Genomics, 2018 Jul 31; 45(7). PMID: 30057342    Free PMC article.
The repertoire of genetic alterations in salivary duct carcinoma including a novel HNRNPH3-ALK rearrangement.
Snjezana Dogan, Charlotte K Y Ng, +13 authors, Jorge S Reis-Filho.
Hum Pathol, 2019 Apr 05; 88. PMID: 30946933    Free PMC article.
Expression of tumor-associated antigens in breast cancer subtypes.
Giuseppe Curigliano, Vincenzo Bagnardi, +7 authors, Giuseppe Viale.
Breast, 2019 Dec 24; 49. PMID: 31869767    Free PMC article.
Statistical modelling of HER2-positivity in breast cancer: Final analyses from two large, multicentre, non-interventional studies in Germany.
Josef Rüschoff, Annette Lebeau, +6 authors, Michael Untch.
Breast, 2020 Jan 10; 49. PMID: 31918324    Free PMC article.
Human epidermal growth factor receptor 2 positive rates in invasive lobular breast carcinoma: The Singapore experience.
Ga-Jing Kee, Ryan Ying-Cong Tan, +11 authors, Guek-Eng Lee.
World J Clin Oncol, 2020 Jul 31; 11(5). PMID: 32728531    Free PMC article.
Propensity score analysis of the prognostic value of genomic assays for breast cancer in diverse populations using the National Cancer Data Base.
Abiola Ibraheem, Olufunmilayo I Olopade, Dezheng Huo.
Cancer, 2020 Jun 11; 126(17). PMID: 32521056    Free PMC article.
Role of tyrosine kinases in bladder cancer progression: an overview.
Amir Sadra Zangouei, Amir Hossein Barjasteh, +2 authors, Meysam Moghbeli.
Cell Commun Signal, 2020 Aug 17; 18(1). PMID: 32795296    Free PMC article.
Evaluation of Next Generation Sequencing for Detecting HER2 Copy Number in Breast and Gastric Cancers.
Dongfeng Niu, Lei Li, +9 authors, Dongmei Lin.
Pathol Oncol Res, 2020 Jul 06; 26(4). PMID: 32621174    Free PMC article.
Human epithelial growth factor receptor 2 in human salivary carcinoma ex pleomorphic adenoma: a potential therapeutic target.
Liang Xia, Yang Wang, +6 authors, Zhen Tian.
Cancer Manag Res, 2018 Dec 18; 10. PMID: 30555262    Free PMC article.
BCL-2 expression aids in the immunohistochemical prediction of the Oncotype DX breast cancer recurrence score.
Mark D Zarella, Rebecca C Heintzelman, Nikolay K Popnikolov, Fernando U Garcia.
BMC Clin Pathol, 2018 Dec 24; 18. PMID: 30574014    Free PMC article.
Tumor Pre-Analytics in Molecular Pathology: Impact on Protein Expression and Analysis.
Veronique M Neumeister, Hartmut Juhl.
Curr Pathobiol Rep, 2019 Jan 01; 6(4). PMID: 30595971    Free PMC article.
Primary systemic therapy in HER2-positive operable breast cancer using trastuzumab and chemotherapy: efficacy data, cardiotoxicity and long-term follow-up in 142 patients diagnosed from 2005 to 2016 at a single institution.
Silvia Antolín, Benigno Acea, +7 authors, Lourdes Calvo.
Breast Cancer (Dove Med Press), 2019 Jan 16; 11. PMID: 30643452    Free PMC article.
Clinical Predictive Factors for the Efficacy of Everolimus in Patients With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer: A Multicenter Retrospective Cohort Study in Japan.
Yuichiro Kikawa, Takeshi Kotake, +5 authors, Masakazu Toi.
Breast Cancer (Auckl), 2019 Feb 09; 13. PMID: 30733627    Free PMC article.
Characterization of Hepatocellular Carcinoma Patients with FGF19 Amplification Assessed by Fluorescence in situ Hybridization: A Large Cohort Study.
Hyo Jeong Kang, Farhan Haq, +12 authors, Eunsil Yu.
Liver Cancer, 2019 Mar 01; 8(1). PMID: 30815392    Free PMC article.
Association of FOSL1 copy number alteration and triple negative breast tumors.
Leandro Tamião Rodrigues Serino, Tayana Schultz Jucoski, +6 authors, Enilze Maria de Souza Fonseca Ribeiro.
Genet Mol Biol, 2019 Mar 01; 42(1). PMID: 30816904    Free PMC article.
Formalin fixation on HER-2 and PD-L1 expression in gastric cancer: A pilot analysis using the same surgical specimens with different fixation times.
Keita Kai, Yukie Yoda, +4 authors, Hirokazu Noshiro.
World J Clin Cases, 2019 Mar 08; 7(4). PMID: 30842953    Free PMC article.
Prognostic significance of tumour-infiltrating lymphocytes for oestrogen receptor-negative breast cancer without lymph node metastasis.
Sasagu Kurozumi, Hiroshi Matsumoto, +6 authors, Hiroyuki Kuwano.
Oncol Lett, 2019 Mar 15; 17(3). PMID: 30867728    Free PMC article.
Predictive and prognostic value of ZEB1 protein expression in breast cancer patients with neoadjuvant chemotherapy.
Ziping Wu, Lei Zhang, +7 authors, Jinsong Lu.
Cancer Cell Int, 2019 Apr 13; 19. PMID: 30976202    Free PMC article.
Evaluation of Formalin Fixation for Tissue Biopsies Using Shear Wave Laser Speckle Imaging System.
Saniel D Lim, Qixuan Huang, Eric J Seibel.
IEEE J Transl Eng Health Med, 2019 May 09; 7. PMID: 31065465    Free PMC article.
A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer.
Tomás Pascual, Miguel Martin, +21 authors, Aleix Prat.
Front Oncol, 2019 May 21; 9. PMID: 31106144    Free PMC article.
Association of ki67 and tumor marker p53 in locally advanced breast cancer patients and evaluation of response to neoadjuvant chemotherapy: a survey in South Iran.
Dena Firouzabadi, Alireza Rezvani, Amirreza Dehghanian, Laleh Mahmoudi.
Cancer Manag Res, 2019 Aug 03; 11. PMID: 31372050    Free PMC article.
Is the frozen section examination for sentinel lymph node necessary in early breast cancer patients?
Kwang Hyun Yoon, Seho Park, +4 authors, Byeong-Woo Park.
Ann Surg Treat Res, 2019 Aug 08; 97(2). PMID: 31388507    Free PMC article.
Comparison of GenesWell BCT Score With Oncotype DX Recurrence Score for Risk Classification in Asian Women With Hormone Receptor-Positive, HER2-Negative Early Breast Cancer.
Mi Jeong Kwon, Jeong Eon Lee, +12 authors, Young Kee Shin.
Front Oncol, 2019 Aug 14; 9. PMID: 31404265    Free PMC article.
Chromogenic in Situ Hybridization Technique versus Immunohistochemistry in Assessment of HER2/neu Status in 448 Iraqi Patients with Invasive Breast Carcinoma.
Ali Hussein Mohammed Ali, Alaa Qasim Yahya, Haider Latteef Mohammed.
Open Access Maced J Med Sci, 2019 Aug 14; 7(12). PMID: 31406529    Free PMC article.
Do early HER2-overexpression breast cancer patients benefit from undergoing neoadjuvant trastuzumab and mastectomy? A meta-analysis.
Lin He, Qian Wu, +3 authors, Yuhua Song.
Cancer Manag Res, 2019 Sep 12; 11. PMID: 31507328    Free PMC article.
Immunohistological Expression of SOX-10 in Triple-Negative Breast Cancer: A Descriptive Analysis of 113 Samples.
Katharina Kriegsmann, Christa Flechtenmacher, +6 authors, Mark Kriegsmann.
Int J Mol Sci, 2020 Sep 10; 21(17). PMID: 32899175    Free PMC article.
Imaging Predictors for Nonsentinel Lymph Node Metastases in Breast Cancer Patients.
Yizi Cong, Suxia Wang, +6 authors, Guangdong Qiao.
Breast Care (Basel), 2020 Sep 29; 15(4). PMID: 32982647    Free PMC article.
Circulating Vitamin D Levels and DNA Repair Capacity in Four Molecular Subtypes of Women with Breast Cancer.
Carmen Ortiz-Sánchez, Jarline Encarnación-Medina, +2 authors, Jaime Matta.
Int J Mol Sci, 2020 Sep 24; 21(18). PMID: 32961801    Free PMC article.
Anti-metastatic action of an N 4-aryl substituted thiosemicarbazone on advanced triple negative breast cancer.
A M Sólimo, M C Soraires Santacruz, +4 authors, M A Callero.
Heliyon, 2020 Oct 20; 6(10). PMID: 33072918    Free PMC article.
Analysis of the serial circulating tumor cell count during neoadjuvant chemotherapy in breast cancer patients.
Sung-Chan Gwark, Jisun Kim, +23 authors, Sei Hyun Ahn.
Sci Rep, 2020 Oct 17; 10(1). PMID: 33060768    Free PMC article.
Upregulation of CCT-3 Induces Breast Cancer Cell Proliferation Through miR-223 Competition and Wnt/β-Catenin Signaling Pathway Activation.
Hongbo Qu, Fang Zhu, +2 authors, Mingli Han.
Front Oncol, 2020 Oct 20; 10. PMID: 33072568    Free PMC article.
Combined CCNE1 high-level amplification and overexpression is associated with unfavourable outcome in tubo-ovarian high-grade serous carcinoma.
Angela My Chan, Emeka Enwere, +16 authors, Martin Köbel.
J Pathol Clin Res, 2020 May 12; 6(4). PMID: 32391646    Free PMC article.
A population-based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with triple-negative breast cancer.
Christine Brezden-Masley, Kelly E Fathers, +3 authors, Katarzyna J Jerzak.
Cancer Med, 2020 Aug 31; 9(20). PMID: 32862501    Free PMC article.
The Case to Case Comparison of Hormone Receptors and HER2 Status between Primary Breast Cancer and Synchronous Axillary Lymph Node Metastasis.
Sasithorn Sujarittanakarn, Wanwisa Himakhun, Worawarn Worasawate, Wilairat Prasert.
Asian Pac J Cancer Prev, 2020 Jun 28; 21(6). PMID: 32592349    Free PMC article.
Expression of MTDH and IL-10 Is an Independent Predictor of Worse Prognosis in ER-Negative or PR-Negative Breast Cancer Patients.
Pei-Yi Chu, Shin-Mae Wang, +2 authors, En-Pei Isabel Chiang.
J Clin Med, 2020 Oct 03; 9(10). PMID: 33003428    Free PMC article.
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer.
Ana C Garrido-Castro, Cristina Saura, +20 authors, Jordi Rodon.
Breast Cancer Res, 2020 Nov 04; 22(1). PMID: 33138866    Free PMC article.
Biomarkers of Targeted Therapy and Immuno-Oncology in Cancers Metastatic to the Breast.
Semir Vranic, Wijendra Senarathne, +3 authors, Zoran Gatalica.
Appl Immunohistochem Mol Morphol, 2019 Sep 14; 28(9). PMID: 31517642    Free PMC article.
Histo- and clinico-pathological analysis of a large series of triple-negative breast cancer in a single center in China: Evidences on necessity of histological subtyping and grading.
Shuang Zhang, Sixia Huang, +8 authors, Ting Li.
Chin J Cancer Res, 2020 Nov 24; 32(5). PMID: 33223753    Free PMC article.
Expression of Immunoproteasome Subunit LMP7 in Breast Cancer and Its Association with Immune-Related Markers.
Miseon Lee, In Hye Song, +6 authors, Hee Jin Lee.
Cancer Res Treat, 2018 Mar 08; 51(1). PMID: 29510614    Free PMC article.
Prognostic Role and Clinical Association of Tumor-Infiltrating Lymphocyte, Programmed Death Ligand-1 Expression with Neutrophil-Lymphocyte Ratio in Locally Advanced Triple-Negative Breast Cancer.
Jieun Lee, Dong-Min Kim, Ahwon Lee.
Cancer Res Treat, 2018 Aug 02; 51(2). PMID: 30064200    Free PMC article.
Significant association of TOX3/LOC643714 locus-rs3803662 and breast cancer risk in a cohort of Iranian population.
Amir Tajbakhsh, Fahimeh Afzal Javan, +8 authors, Alireza Pasdar.
Mol Biol Rep, 2018 Dec 06; 46(1). PMID: 30515698
An Introduction to the Performance of Immunohistochemistry.
Shino Magaki, Seyed A Hojat, +2 authors, William H Yong.
Methods Mol Biol, 2018 Dec 13; 1897. PMID: 30539453    Free PMC article.
HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma.
Patrick Sven Plum, Florian Gebauer, +10 authors, Heike Loeser.
BMC Cancer, 2019 Jan 10; 19(1). PMID: 30621632    Free PMC article.
Bcl-2 expression and prognostic significance in feline invasive mammary carcinomas: a retrospective observational study.
Elie Dagher, Jérôme Abadie, +3 authors, Frédérique Nguyen.
BMC Vet Res, 2019 Jan 12; 15(1). PMID: 30630524    Free PMC article.
SOX10 expression in mammary invasive ductal carcinomas and benign breast tissue.
Kenrry Chiu, Diana N Ionescu, Malcolm Hayes.
Virchows Arch, 2019 Mar 25; 474(6). PMID: 30903273
miR-106b-5p and miR-17-5p could predict recurrence and progression in breast ductal carcinoma in situ based on the transforming growth factor-beta pathway.
Jieun Lee, Hee Eun Kim, +2 authors, Ahwon Lee.
Breast Cancer Res Treat, 2019 Apr 17; 176(1). PMID: 30989460    Free PMC article.
Association of p53 expression with poor prognosis in patients with triple-negative breast invasive ductal carcinoma.
Jing-Ping Li, Xiang-Mei Zhang, +3 authors, Yun-Jiang Liu.
Medicine (Baltimore), 2019 May 03; 98(18). PMID: 31045815    Free PMC article.
Association of Cytokeratin 5 and Claudin 3 expression with BRCA1 and BRCA2 germline mutations in women with early breast cancer.
Sabine Danzinger, Yen Yen Tan, +4 authors, Christian F Singer.
BMC Cancer, 2019 Jul 17; 19(1). PMID: 31307407    Free PMC article.
A multiple breast cancer stem cell model to predict recurrence of T1-3, N0 breast cancer.
Yan Qiu, Liya Wang, +8 authors, Hong Bu.
BMC Cancer, 2019 Jul 26; 19(1). PMID: 31340763    Free PMC article.
Ki67 index in intrinsic breast cancer subtypes and its association with prognostic parameters.
Atif Ali Hashmi, Kashif Ali Hashmi, +7 authors, Amir Khan.
BMC Res Notes, 2019 Sep 25; 12(1). PMID: 31547858    Free PMC article.
Clinical Outcomes of 130 Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Treated with Palbociclib plus Endocrine Therapy and Subsequent Therapy: A Real-World Single-Center Retrospective Study in China.
Chang Liu, Ting Li, +5 authors, Xichun Hu.
Med Sci Monit, 2020 Dec 01; 26. PMID: 33250509    Free PMC article.
Human epidermal growth factor receptor 2 (HER2) gene amplification in non-muscle invasive urothelial bladder cancers: Identification of patients for targeted therapy.
Vinita Agrawal, Niharika Bharti, Rakesh Pandey.
Arab J Urol, 2020 Dec 15; 18(4). PMID: 33312739    Free PMC article.
Genetic analysis of pleomorphic and florid lobular carcinoma in situ variants: frequent ERBB2/ERBB3 alterations and clonal relationship to classic lobular carcinoma in situ and invasive lobular carcinoma.
Eliah R Shamir, Yunn-Yi Chen, Gregor Krings.
Mod Pathol, 2020 Jan 08; 33(6). PMID: 31907376
HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy.
Douglas Rottmann, Olivia L Snir, +4 authors, Natalia Buza.
Mod Pathol, 2019 Sep 04; 33(1). PMID: 31477811
Concordance of the 21-gene assay between core needle biopsy and resection specimens in early breast cancer patients.
Peng Qi, Yu Yang, +5 authors, Xiao-Yan Zhou.
Breast Cancer Res Treat, 2021 Jan 14;. PMID: 33439420    Free PMC article.
The prognosis of early-stage breast cancer in extremely young female patients.
Wei-Pang Chung, Kuo-Ting Lee, +4 authors, Hui-Ping Hsu.
Medicine (Baltimore), 2021 Jan 13; 100(1). PMID: 33429771    Free PMC article.
[Molecular subtypes of urothelial carcinoma of the bladder-background and clinical relevance].
Philipp Erben, Christoph Becker, +3 authors, Fachgruppe Molekulare Urologie der Arbeitsgruppe urologische Forschung (AuF) der Deutschen Gesellschaft für Urologie.
Urologe A, 2020 Nov 27; 60(1). PMID: 33242119
Survival Rates of Breast Cancer Patients Aged 40 to 49 Years according to Detection Modality in Korea: Screening Ultrasound versus Mammography.
So Yeon Won, Hyung Seok Park, +8 authors, Byeong Woo Park.
Korean J Radiol, 2020 Sep 10; 22(2). PMID: 32901456    Free PMC article.
Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer.
Denis M Collins, Stephen F Madden, +20 authors, John Crown.
Clin Cancer Res, 2020 Oct 31; 27(3). PMID: 33122343    Free PMC article.
HER2-Positive Breast Cancer Patients with Pre-Treatment Axillary Involvement or Postmenopausal Status Benefit from Neoadjuvant Rather than Adjuvant Chemotherapy Plus Trastuzumab Regimens.
Enora Laas, Arnaud Bresset, +8 authors, Anne-Sophie Hamy.
Cancers (Basel), 2021 Jan 28; 13(3). PMID: 33498405    Free PMC article.
Indication of high lipid content in epithelial-mesenchymal transitions of breast tissues.
Siti Norbaini Sabtu, S F Abdul Sani, +4 authors, Z Osman.
Sci Rep, 2021 Feb 07; 11(1). PMID: 33547362    Free PMC article.
Sensitive sandwich-type voltammetric immunosensor for breast cancer biomarker HER2 detection based on gold nanoparticles decorated Cu-MOF and Cu2ZnSnS4 NPs/Pt/g-C3N4 composite.
Mehmet Lütfi Yola.
Mikrochim Acta, 2021 Feb 12; 188(3). PMID: 33569679
Validation of the Role of Thrombin Generation Potential by a Fully Automated System in the Identification of Breast Cancer Patients at High Risk of Disease Recurrence.
Patricia Gomez-Rosas, Marina Pesenti, +19 authors, HYPERCAN Investigators.
TH Open, 2021 Feb 16; 5(1). PMID: 33585786    Free PMC article.
A population-based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with hormone receptor-positive/HER2-negative breast cancer.
Christine Brezden-Masley, Kelly E Fathers, +3 authors, Katarzyna J Jerzak.
Breast Cancer Res Treat, 2020 Oct 17; 185(2). PMID: 33064230    Free PMC article.
Efficacy of second-line treatments for patients with advanced human epidermal growth factor receptor 2 positive breast cancer after trastuzumab-based treatment: a systematic review and bayesian network analysis.
Fei Chen, Naifei Chen, +2 authors, Jiuwei Cui.
J Cancer, 2021 Feb 23; 12(6). PMID: 33613756    Free PMC article.